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Abstract
Background: Medications benefit people with diseases and medical conditions,
improving many patients' lives and in some cases significantly increasing their quality
of life. Despite these great benefits, medications can lead to serious adverse effects.
Adverse drug reactions (ADRs) are the

4th

leading cause of death, greater than major

killers including pulmonary diseases, diabetes and automobile death. Not all
medication groups have the same incidence in inducing diseases. Anti-infective agents
- including antibacterial agents- are the most likely to induce diseases followed by
cardiovascular agents and antineoplastic agents.

Objectives: Drug safety is a very important issue in patient therapy. Since
antibacterial agents in general and fluoroquinolones specifically are among the most
prescribed medications, it is very important to quantify their risks in causing serious
adverse reactions such as hepatotoxicity and pancreatitis. In terms of drug safety and
preventing ADRs, costs are a very important factor because many conditions like
hypoglycemia can be prevented, leading to significant decreases in cost and
improvement in quality of life. Since there is a dearth of research that has examined
these areas, epidemiological studies are needed. The objectives of the three proposed
manuscripts of this dissertation were to a) estimate the risk of hepatotoxicity
associated with fluoroquinolones use; b) examine antibacterial agents use and the risk
ofacute pancreatitis development; c) review the healthcare databases in United States
and European countries that are commonly utilized in conducting epidemiological
research.

Methods: Two matched case control studies were used to examine the risk of
hepatotoxicity and acute pancreatitis development with using fluoroquinolones and
antibacterial agents, respectively. The Veterans' Affairs (VA) medical database was
used to perform the two studies. Odds ratios (OR) and their 95% confidence intervals
(CI) were derived from crude and adjusted conditional logistic regression models. In
the third paper, a literature search was performed using Publisher Medline (Pubmed),
Embase® and the Iowa Drug Information Services (IDIS) to perform a review of four
medical databases including the Nationwide Inpatient Sample database, the Veterans'
Affairs medical database, the Health Improvement Network database and the
Norwegian medical database.

Results: In the first study, fluoroquinolones use was associated with increased risk of
hepatotoxicity. However, only ciprofloxacin was statistically significantly associated
with development of hepatotoxicity while levofloxacin and moxifloxacin were not
associated with hepatotoxicity development. In the second study, use of antibacterial
agents was associated with increased risk of acute pancreatitis.

Conclusion: The findings fro in both studies show that antibacterial agents are
associated with increased risk of hepatotoxicity and acute pancreatitis. Knowing the
safety of medication is very important for the clinical practice especially for
antibacterial agents since they are commonly used and clinicians are considering these
agents very safe. However, further research is needed to confirm these findings and to
understand the biological mechanism behind their toxicity.
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Preface
All three Chapters in this dissertation were prepared following the manuscript format
for each journal.

Chapter I: Estimating the Risk ofHepatotoxicity Associated with Fluoroquinolone
Use: A Case-Control Study Using the National Veterans Affairs Database. The
Journal of the American Medical Association (JAMA) format

Chapter II: Antibacterial use and risk of acute pancreatitis: A Case-Control Study
Using the National Veterans Affairs Database. Clinical Infectious Diseases (CID)
format

Chapter III: Review the healthcare databases in United States and European countries
that are commonly utilized in conducting epidemiologic research.
Pharmacoepidemiology and Drug Safety (PDS) format.
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CHAPTER I
Estimating the Risk of Hepatotoxicity Associated with Fluoroquinolone Use:
A Case-Control Study Using the National Veterans Affairs Database

This manuscript will be submitted to the Journal of the American Medical Association
(JAMA)

1

Abstract
Context: Health care agencies across the world are closely monitoring reports of
hepatotoxicity linked with fluoroquinolone use. Medications and herbal remedies
currently account for fifty percent of acute liver failure in the United States and liver
toxicity is one of the most common reasons for drug removal by the FDA. The
incidence of hepatotoxicity due to fluoroquinolone use is currently unknown.

Objective: To assess the risk of hepatotoxicity in patients using fluoroquinolones
compared to patients who did not use fluoroquinolones among patients admitted to
Veterans Affairs facilities nationally.

Design, setting and patient: Matched case control design was used to evaluate a
national cohort of patients admitted to all Veterans Affair facilities between January
15\ 2002 and December 31 5\ 2008. Patients diagnosed with hepatotoxicity as primary
diagnosis served as cases and patients diagnosed with myocardial infarction served as
the control group. Conditional logistic regression was utilized to compute odds ratios
and the 95% confidence interyal (CI). Multivariable models were built to adjust and
control for the potential clinical conditions or covariates that might influence
hepatotoxicity risk. A stepwise forward entry method (non-computer generated) was
used to build the final model.

Main Outcome Measure: The risk of hepatotoxicity associated with fluoroquinolone
use.

Results: A total 7,862 patients in the hepatotoxicity-case group and 45,512 patients in
control group were entered in the final analysis. The mean age of the cases was 58
2

years and the majority of the patients were males (96%) and were white (59%),
followed by black race (18%) and hispanic (4%). After adjusting for potential
confounders, tluoroquinolone use was significantly associated with increased risk of
developing hepatotoxicity, odds ratio (OR) was 1.196 (95% Confidence Interval [CI],
1.039-1.3 75). Further, ciprofloxacin was significantly associated with risk of
hepatotoxicity, OR, 1.294 (95% CI 1.051-1.58).
Conclusion: The use of fluoroquinolones was associated with increased risk of

hepatotoxicity among a national cohort of veterans.

3

Background
Hepatotoxicity, defined as an injury to the liver cells is commonly associated
with a decrease in liver function.

1

The liver's metabolism and connection with the

gastro-intestinal tract increases susceptibility to injury from drugs and other ingested
substances. Hepatotoxicity can range from a mild reaction, which can be resolved by
discontinuation of the causative agents to a serious fatal reaction. 2 Medications, herbs,
chemicals and infectious pathogens are the most common causes of hepatotoxicity. 3-7
Although the incidence of drug induced- hepatotoxicity is considered rare -1 in 10,000
to 1 in 100,000- it is usually clinically significant.

8

Fifty percent of acute liver failure cases are caused by medications and 5% of
all hospital admissions are caused by drug-related hepatotoxicity. 9 Currently,
hepatotoxicity is the leading cause of acute liver failure in the United States (US).
Acute Liver Failure (ALF) due to medications is usually a fatal reaction and only 20%
of patients will respond to therapy and survive.2 Liver damage due to drugs has
different features: hepatocellular, cholestatic or a.mixture ofboth. 10- 12 There is no
specific treatment for drug-induced hepatotoxicity in most cases; supportive care and
withdrawal of causative agent are the only treatment options available. More than 900
drugs can cause hepatotoxicity. 13 As a cost ofliver toxicity, the average cost of treating
a patient with acute liver failure using 2001 and 2006 data is estimated at is $146,972
to $252, 113.

14 15
,

Fluoroquinolones are antimicrobial agents that possess a broad spectrum of
activity against gram-negative and gram-positive organisms. These drugs are widely

4

used to treat nosocomial and community acquired infections.
.
one of the most prescn"bed me d"1cat1ons.

16

Fluoroquinolones are

17

Antimicrobial agents, including fluoroquinolones are the most common cause
of non-acetaminophen induced hepatotoxicity.

18

Antimicrobial induced hepatotoxicity

usually is an idiosyncratic reaction, dose independent and unrelated to intended
pharmacological effect.

18 19
'

In the past decade, liver toxicity has been one of the most

common reasons for drug removal from the U.S. market by the FDA such as
troglitazone (Rezulin®).

18

In the United Kingdom (UK), the Medicines and Healthcare products
Regulatory Agency (MHRA) restricted the indication of moxifloxacin for use only
when other antibiotics failed to treat acute bacterial sinusitis, acute exacerbation of
chronic bronchitis or community acquired pneumonia due to the risk of hepatotoxicity
associated with moxifloxacin.

20

Increases in the reports ofhepatotoxicity associated with the usage of
fluoroquino lones are a crucial issue in clinical practice, since fluoroquino lones are
commonly prescribed because of their broad spectrum of coverage. At the same time
liver toxicity is a serious issue and 50% of cases are related to medication and not
related to any underlying diseases. However, in the case reports, the association
between fluoroquinolones and hepatotoxicity is unclear. 21 -24 A well designed
epidemiological study is necessary to assess the possible increased risk of
hepatotoxicity associated with fluoroquinolones usage. Therefore, the purpose of this

5

study was to conduct a real-world safety study to assess the association between
fluoroquinolones use and risk ofhepatotoxicity.

6

Methods
Data source

In United States, the Veterans Affairs (VA) medical database is considered
from the largest medical database with information for more than 7.9 million veterans.
2s-27

These data include detailed information on all medical and pharmacy information

for each patient. All patient data are stored in electronic form.

28 29
'

Additionally,

Veteran Health Administration (VHA) runs and operates over 164 hospital and 800
clinics with more than 180,000 medical personnel. All data are maintained on three
levels: the local level, the VA Integrated Services Networks (VISN) level, and the
national level. 30 Every patient treated in any VA hospital or other VA facilities has
his/her information collected and stored in the National Patient Care Database
(NPCD), the source data for the VHA medical SAS datasets. Similar to many other
medical databases, VHA uses the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM ) to code all diseases, procedures, and
surgeries in the VA datasets. In addition, the Current Procedure Terminology (CPT)
code system is used to code some procedures in the medical SAS outpatient datasets.
31

The Diseases coding in the VA database h~s been validated and determined to be of

high quality.

30 32
,

Study design

A matched case-control study was utilized using a national cohort of patients
in the VA databases (hospital and pharmacy data) which contain preexisting data to
examine the association between fluoroquinolone use and development of
7

hepatotoxicity. Scrambled Social Security numbers were used to guarantee the privacy
of the patients. The study was approved by the Institutional Review Board (IRB) of
the y A research committee and the research office at the University of Rhode Island.

Cases and controls
Our patient cohorts were taken from the national VA database in Austin
(Austin Automation Center; AAC) between January 1st, 2002 and December 31st,
2008. All patients from the study population diagnosed with hepatotoxicity as primary
diagnosis were defined as our case patients. Only the first diagnosis for hepatotoxicity
was considered in the instance of patients who have multiple episodes during the study
period. Hepatotoxicity term included "hepatotoxicity, acute necrosis of the liver, liver
toxicity and toxic hepatitis". Hepatotoxicity cases were identified using ICD-9-CM
codes: hepatic necrosis (570) and toxic hepatitis (573.3).

6 33 35
' -

For each case patient

we randomly selected up to six controls from the population of patients who were
diagnosed as primary diagnosis with myocardial infarction (ICD-9-CM 410.00410.92). We have chosen myocardial infarction because it has the same
hepatotoxicity characteristics ·which are acute and serious outcome. For both cases
and controls, patients with secondary diagnoses for infectious diseases are allowed to
be included in our study. Controls were match to cases based on month ofadmission.
We excluded individuals who meet one of the following criteria: liver
cirrhosis, liver cancer, any type of viral hepatitis, alcoholic hepatotoxicity,
acetaminophen induce-hepatotoxicity, human immunodeficiency virus/acquired
immunocompromised deficiency diseases HIVIAIDS, liver abscess and Wilson's

8

disease. Also, we excluded patients who were hospitalized during the 180 days prior to
the admission date.

Exposure definition
Definition of drug exposure was as patient received a prescription for
ciprofloxacin, levofloxacin, or moxifloxacin six months prior to the admission date.
Medications were identified using drug description variables along with intermediate
product number (IPNUM) variable. Only outpatients' medications were included in
the study and most of fluoroquinolones used were oral medications.

Covariates
Covariates that were controlled in the logistic regression model include age,
gender, race, alcohol status ( ICD-9 codes (305.0, 303.0, VI 1.3, V79.1), alcohol
dependency treatment (BEDSECN=725) and alcohol-related DRGs (DRG=433)),
smoking status, illicit drug use, comorbidities (history of diabetes, renal diseases ,
hypotension, heart failure, gall bladder disease), medications' prescription data for our
cases and controls included: tetracyclines, macrolides, amoxicillin,
amoxicillin/clavulanic acid, isoniazid , rifampicin, pyrazinamide, ethambutol,
antifungal medications, thiazolidinediones, metformin, Proton Pump Inhibitors (PPis)
and phenytoin. These medications were selected because they are known to cause
hepatotoxicity.

1

9

Data Analyses

The primary analysis of the study was to examine the association between the
development of hepatotoxicity and exposure to fluoroquinolone use. Demographic and
2

clinical categorical data was analyzed using X test or Fisher's exact test while
continuous variables were analyzed using a student's t-test or Mann Whitney test.
Conditional logistic regression was used to compute odds ratio and their 95%
confidence interval (CI) . Bivariate analyses were initially used for the selection of
potential clinical covariates for inclusion in the multivariable model. Based on the
findings of the bivariate analyses, a multivariable model was built to control for the
potentially confounding variables. Covariates with differences of I 0% between the
cases and controls were included in the multivariable model. A forward entry method
(non-computer generated) was used to build the final model, at each step, a covariate
was added, and ifthe estimated coefficient (B) of fluoroquinolone exposure changes
by> I 0%, this covariate was kept in the final model. Potential effect modifiers were
examined by adding specific interaction terms to the conditional logistic regression
models. At each step, an interaction term was added to the model and the interaction
will be significant if the estimated coefficient (B) of fluoroquinolone exposure changes
by> I 0%. Presence of collinearity was assessed by Variation Inflation Factor (VIF)
using value of 2.5 as cut off

36

All the confounders or covariates were assessed at

baseline. Subgroup analysis was conducted to study the association between each
drug (ciprofloxacin, levofloxacin and moxifloxacin) and their risk of hepatotoxicity.
All statistical tests were conducted with a two-tailed alpha of 0.05 using SAS®
version 9 .1.3 (SAS® Institute, Inc, Cary, NC).
10

Results
There were 21,404 case patients identified with hepatotoxicity. We excluded
patients with liver cancer (n=l,033), patients with liver cirrhosis and hepatotoxicity
due to alcohol (n=9,543), patients with HIV/AIDS and Wilson's disease (n=349),
patients with viral hepatitis (n=l,302), patients with liver abcess (n=48), patients with
acetaminophen induced hepatotoxicity (n=l 83) and any patient admitted in the last 6
months prior to the admission date (n=l,084). 7,862 patients were included in the final
analysis as case group. The majority of our study population was male (96%) and the
mean age was 58 years for cases and 64 for controls. Approximately, 60% ofcases
were of white race followed by 17% black. In comparison to the cases, in the control
group, 64% of patients were white and 11 % black (Table I. I);. In both cases and
controls, approximately 20% of race is missing which is acceptable if we consider the
fact that most of administrative databases did not include race. The cases tend to use
alcohol and illicit drug more than controls while control tend to smoke tobacco more
than cases.
Patients in control group had a higher prevalence of diabetes mellitus (33%) in
comparison to patients in case group (22%) while prevalence of renal disease was
more in cases (13%) than controls (6%). Other comorbidities were almost the same
between the cases and controls.
Medication consumptions were similar between the patients in case group
compared to the patients in control group with few exceptions. The percentage of
patients using hypoglycemic agents ''thiazolidinedione and metformin" was more in

11

controls (3%, 10%, respectively) compared to cases (1.5, 4.5%, respectively). On the
other hand, phenytoin was used more in cases (0.80%) compared to controls (0.5%).
The other medication groups such as tetracyclines, macrolides, amoxicillin/
amoxicillin+ clavulnate, anti-tuberculosis medications and antifungal were almost
similar between cases and controls.
Odds ratios (OR) and the 95% confidence intervals (CI) were computed from
the crude and the adjusted conditional logistic regression models. There was a
statistically significant association between fluoroquino lones use and developing
hepatotoxicity after adjusting for all potential confounders, the adjusted OR was 1.196
(95% CI: 1.039-1.3 75) (Table 1.2). Secondary analysis was done to estimate the risk of
hepatotoxicity with drugs of interests (ciprofloxacin, levofloxacin and moxifloxacin)
compared to non users. Ciprofloxacin was statistically significant associated with
hepatotoxicity OR 1.294 (95% CI 1.051-1.586) (Table 1.3). Further, levofloxacin and
moxifloxacin were associated with hepatotoxicity as indicated by an OR of 1.164
(95% CI 0.941-1.439) and OR of 0.98 (95% CI 0.67-1.416) respectively, but these
associations were not statistically significant. There was no collinearity between the
variables in our model.

12

Discussion
To our knowledge, this is the first study to examine the association between
fluoroquinolone antibiotic use and the risk of developing hepatotoxicity. This study
utilized an extremely large database.

11

Our population was mainly white and male as

expected since most of the patients were veterans. Patients with hepatotoxicity in our
study were younger than the controls. This is consistent with many case reports and
studies that assess the association between hepatotoxicity and medications.
Hepatotoxicity can develop at any age.

2

2 23 37 38
, , ,

Based on the results of our study, we found

that patients with hepatotoxicity are 1.196 times more likely to have been exposed to
fluoroquinolones than control group. Our results indicate that fluoroquinolones use is
associated with risk of developing hepatotoxicity. Furthermore, the results showed
that ciprofloxacin is significantly associated with risk of developing hepatotoxicity
while levofloxacin and moxifloxacin were not statistically significant associated with
hepatoto xic ity.
Gatifloxacin was not included in the study ·because it is no longer actively
marketed after the 2006. Gatifloxacin had a "Black Box" warning regarding increased
dysglycemias in diabetic patients before the company stopped manufacturing the
drug.39

These observed associations between fluoroquinolones are biological
plausible. Ciprofloxacin and moxifloxacin are partially metabolized by the liver while
levofloxacin is largely execreted unchanged by the kidneys.

40 2
-4

Liver enzymes

elevation occurred in 2-3% of patients with fluoroquinolones. Alanine

13

aminotransferase, aspartate aminotransferase, and alkaline phosphatase are the most
. 1ones use.
reported elevated enzymes wit. h fl uoroqumo

43 44

'

In humans, t he

intrahepatic concentrations of fluoroquinolones have been found to be eight times as
their concentration in the serum.

45

Increasing the concentration of fluoroquinolones in

the liver might lead to hepatic injury. However, the liver toxicity usually occurred
when the concentration is 20 times intrahepatically compared to serum concentration.
45

Therefore, this may be the reason why ciprofloxacin is associated with

hepatotoxicity and levofloxacin was not. However, moxifloxacin was not associated
with hepatotoxicity while it is metabolized by liver; this may be because of the small
number of patients using moxifloxacin. A possible explanation is that, until, 2006,
ciprofloxacin and gatifloxacin were the fluoroquinolones of choice within the VA
facilities. Ciprofloxacin was the least expensive drug since it was available as generic.
46 47
•

Although, there was a new restriction in using moxifloxacin in UK, a recent

European review assessed the risk of moxifloxacin safety compared to other
fluoroquinolones. Researchers conclude that hepatotoxicity with moxifloxacin was not
different than other fluoroquinolones.

48

In addition to the metabolism effect

mechanism, some literature suggested that fluoroquinolones hepatotoxicity is a
idiosyncratic drug reaction "immune-mediated" manifested by eosinophilia.

49

This

mechanism could be the suggested mechanism in the case of medication that is mainly
eliminated by renal routes such as levofloxacin.
Although, there is no study to assess the association between fluoroquinolones
use and risk of hepatotoxicity, SB Meropol et al, compared the incidence rate of
hepatotoxicity with using three different medications which are ciprofloxacin ,

14

amoxicillin and doxycycline.

50

They compared the incidence of hepatotoxicity with

these medications in three different databases. Overall, the incidence rate of
hepatotoxicity was more with ciprofloxacin compared to amoxicillin and doxycyline
(20.6, 1.4, Oper 100,000 person day, respectively). The results of this study were
consistent with our study results. Many case reports questioned the risk of
hepatotoxicity with fluoroquinolone drugs including, ciprofloxacin, moxifloxacin, and
levofloxacin.

23 24 38 51
' ' '

Contreras et al, describe a 32 year old male who was diagnosed

with septic arthritis in his ankle. He started ciprofloxacin ( 500 mg q 12h) and
subsequently, the patient developed jaundice, his liver enzymes goes up (AST: 1, 782
U/L (normally< 35) and ALT:2, 144 U/L (normally< 40). The patient was suspected
to have ciprofloxacin induce liver failure and admitted to intensive care unit (ICU).
The patient started to improve and his liver enzymes return to the normal after 6 weeks
of discontinuing ciprofloxacin.

52

Schwalm and Lee describe a 73 year old male who

developed acute hepatitis after using levofloxacin 250 mg orally per day. He was
started on levofloxacin for cellulitis and shortly after initiation oflevofloxacin, his
liver enzymes increased (AST: 1392 U/L and ALT: 857 U/L). Levofloxacin was
stopped and within 1 week, the enzymes returned to near normal levels

53

.The time of

hepatotoxicity in these reports varied between 5 and 35 days.
Our results indicate that Veterans of Asian race were not at greater risk of
developing hepatotoxicity compared to black and Hispanic veterans. This result is
consistent with the fact that Asian patients tend to have faster metabolism compared to
other races.
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While, the Native American patients have the highest risk compared to

other races, this is may be due to different reasons such; Native Americans are using

15

many herbs as treatment and as nutritional supplement and these herbs could have an

.

effect on t he 11ver.
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Patients with myocardial infarction were chosen as the control group because
they are believed to have many similar characteristics to those with hepatotoxicity,
including acute onset and serious outcome. In a case control study, having an
appropriate control group is challenging.
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Other controls such as those with renal

diseases cannot be used because there is an association between fluoroquinolones
medication use and the development of renal diseases. 57 ' 58 Additionally, patients with
injury are not a suitable group because those patients usually have severe
comorbidities and may be older.
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One quarter of veterans who served at Iraq and

Afghanistan are reported to have head and neck injury type, just one type of the many
. . . 60-62
poss1.ble mJunes.
In our study, we controlled for covariates (social behavior, health conditions
and medications) that might influence hepatotoxicity. Further, we controlled for the
possible interactions (2-way and 3-way) to minimize the role of effect modifiers.
Observational studies, especially those that assess the effects of medications,
should evaluate the potential of confounding by indication, when seriously ill patients
being more likely to receive fluoroquinolone medications and more likely to develop
the outcome. To assess this, first we excluded any patient who has been admitted in
the hospital to avoid including any very ill patient. Additionally, we were able to
exclude many major risk factor for hepatotoxicity such as viral hepatitis and liver
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abscess and finally we controlled for most of relevant comorbidities in our regression
model.
The recognized association between fluoroquino lones and hepatotoxicity is not
new. Trovafloxacin was the first drug from fluoroquinolone medications that
associated with hepatotoxicity.

63

Trovafloxacin is available with special restrictions

for use only in patients with life-threatening or limb infections because of serious liver
toxicity including hepatitis, liver failure that resulted in liver transplantation and death.
64 ,65

In 1999, trovfloxacin was removed from European market because of liver

• •

tox1c1ty.
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Our study has several strengths; we utilized a large database with sufficient
power to assess the association between fluoroquinolones use and risk of developing
hepatotoxicity. Moreover, this database allowed us to include patients that may not be
in other databases, such as those of Native American race and users of illicit drugs.
We were able to control for many major potential confounders such as liver cancer,
liver cirrhosis and other risk factors.
However, our study has several limitations. Since we are using an
administrative database, there is potentially a problem with coding and missing data,
especially for behavioral variables such as alcohol abuse and tobacco smoking. In the
VA database, there are specific variables for alcohol abuse and tobacco use but these
variables usually are missing at least in the case of our study. Instead, we used ICD-9-

CM codes to detect patients who are smoking tobacco, who have history of smoking
and patients who are abuse alcoho I. We believe that there may be a an underestimation
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of the prevalence of these behaviors. Additionally, illicit drug use is determined by
patients (self identified), not by using analytical test to test these substances in the
blood. Using this method could underestimate illicit drug use and we speculate that
not all patients will identify if they use illicit drugs or not. The validity of the ICD-9CM code as an indicator for hepatotoxicity is not known. In general, the validity of
different ICD-9 codes varies.

67 68
'

However, it is unlikely that hepatotoxicity is

ignored as a diagnosis. Another limitation of using administrative database is that we
can't determine whether patients receiving fluoroquinolones actually took their
medications and adhered to their medication regimen .. The majority of our population
in the study are veterans males, therefore we may not generalize our results to women
and non-veteran patients.
Finally, as with other observational studies, residual confounding cannot be
completely excluded.
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Conclusion
In conclusion, it was found in a large national cohort study that fluoroquinolones use
is significantly associated with the risk of developing hepatotoxicity compared to nonuse. Furthermore, ciprofloxacin was statistically significant associated with the risk of
hepatotoxicity compared to non-users. At present, it is believed that clinicians should
be aware of this potential issue when they prescribe fluoroquinolones in patients who
are at risk of developing hepatotoxicity. Thus, further research is needed to confirm
these findings and to better understand the underlying mechanism.
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Table 1.1: Demographic and clinical characteristics' among patients with
hepatotoxicity (cases) and patients with myocardial infarction (controls) in
Veterans Affairs database between Jan 2002- Dec 2008.
Cases
Controls
P value
N=45,512 (%)
N=7,862 (%)
Age, mean (SD)

58.4

(12.7)

63.8

(11.0)

Sex (%male)

96.30%

98.00%

4,621 (58.9%)
1,401 (17.8%)
37 (0.47%)
329 (4.2%)
52 (0.7%)
1,422 ( 18%)

29,227 (64.2%)
4,990 (10.9%)
227 (0.49%)
1,264 ( 2.9%)
122 ( 0.3%)
9,685 (21.3%)

<0.01
<0.01

Race
White
Black
Asian
Hispanic
Native American
Unknown
Alcohol abuse*

493 ( 6.3%)

<0.01

280 ( 0.6%)

Smoking*
Never
Current
Past
Illicit drug use

6,946 (88.4%)
805 (10.2%)
112 ( 1.4%)
144 ( 1.8%)

38,562 (84.7%)
5,504 (12.9%)
1,453 ( 3.2%)
160 (0.35%)

<0.01

Comorbidities
Diabetes Mellitus
Hypotension
Gall bladder disease
Renal Diseases
Heart failure

1,787 (22.7%)
219 ( 2.8%)
292 ( 3.7%)
1,02~ ( 13%)
871 (11.1 %)

15, 104
1, 137
407
2,743
5,207

<0.01
0.13
<0.01
<0.01
0.35

Prescription medications§
Tetracyclines
MacroIides
Amoxicillin±cal vulante
Anti-TB
Anti fungal
Thiazolidinediones
Metformin
Statins
Proton pump inhibitors
Phenytoin
*Based on ICD-9-CM

81 ( 1%)
212 (2.7%)
169 (2.15%)
10 (0.13%)
25 (0.32%)
125 (1.5%)
359 (4.5%)
717 (9.2%)
858 (10.9%)
60 (0.8%)

(33%)
(2.5%)
(0.9%)
( 6%)
(11.4%)

<0.01

535 (1.2%)
0.26
1,231 (2.7%)
1.00
1,082 (2.4%)
0.21
32 (0.07%)
0.09
87 (0.2%)
0.02
1,418 ( 3%)
<0.01
4,566 (10%)
<0.01
10,469 (23%)
<0.01
6,493 (14.3%)
<0.01
217 (0.48%)
0.01
§Medications known to cause hepatotoxicity
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Table 1.2: The result of multivariable model showing the risk of hepatotoxicity
associated with fluoroquinolones (the crude and adjusted odd ratios of study
outcomes).
Crude Odds Ratio
Adjusted Odds Ratio
Variable
(95%CI)*
(95%CI)
Fluroquino lones

1.125 (0.98-1.287)

1.196 (1.039-1.375)

Age

0.958 (0.956-0.961)

0.954 (0.951-0.957)

Gender¥

1.934 ( 1.688-2.216)

1.509 (1.299-1. 753)

1.534
1.673
1.100
2.140
0.948

1.4 73
1.686
1.225
2.320
0.94 7

Race§
Black
Hispanic
Asian
Native American
Unknown

( 1.430-1.646)
(1.469-1.904)
(0. 767-1.577)
(1.514-3.025)
(0.886-1.016)

( 1.369-1.570)
(1.471-1.932)
(0.845-1. 775)
(1.605-3.355)
(0.885-1.014)

n

8.363 (7.168-9. 757)

7.770 (6.629-9.108)

Current smoker

0.642 (0.590-0.698)

0.637 (0.585-0.693)

Ex smoker

0.451 (0.3 70-0.550)

0.511 (0.414-0.629)

Diabetes mellitus

0.627 (0.592-0.664)

0.674 (0.632-0. 719)

Renal diseases

2.992 (2. 759-3 .246)

3.151 (2.894-3.431)

Gall bladder diseases

4.740 (4.040-5.562)

4.709 (3.994-5.553)

Metformin

0.622 (0.550-0.704)

0.644 (0.569-0.728)

Stat in

0.372 (0.343-0.404)

0.420 (0.385-0.460)

Antifungal

1.539 (0.970-2.444)

1.666 (1.033-2.687)

PPI

0.779 (0.721-0.843)

0.845 (0.779-0.917)

Alco ho 1abuse
Smoking$

*Adjusted for all potential confounders in the table
¥ The reference group is male gender
§The reference group is white race
$Compared to people who never smoke using ICD-9-CM
21

Table I.3: Risk estimates for hepatotoxicity among users of different
fluoroquinolones.
Cases (n=7,862) Control (n=45,512)
Adjusted Odds
Drug
Ratio (95%CI)
651
1.29 (1.05-1.58)
124
Ciprofloxacin *
Levofloxacin§

112

696

1.16 (0.94-1.44)

Moxiflo xacin t

36

256

0.98 (0.67-1.41)

*Multivariable model adjusted for age, gender, race, smoking, alcohol abuse, diabetes
mellitus, renal diseases, metformin use and proton pump inhibitors (PPis) use.
§Multivariable model adjusted for age, gender, race, alcohol abuse, diabetes mellitus,
renal disease, gall bladder diseases metformin use and PPis use.
t Multivariable model adjusted for age, gender, race, alcohol abuse, diabetes mellitus,
renal diseases and proton pump inhibitors (PP Is) use
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CHAPTER II
Antibacterial use and risk of acute pancreatitis: A Case-Control Study Using the
National Veterans Affairs Database
This manuscript will be submitted to the Clinical Infectious Diseases (CID) journal
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Abstract
Background: Acute pancreatitis is most commonly seen among persons who have

gall bladder diseases or abuse alcohol. Medications, including antibacterial agents
have also been reported to cause acute pancreatitis. This requires the Food and Drug
Administration to focus on the risk of acute pancreatitis with these medication classes.
Although there are many case reports discussing the risk of acute pancreatitis with
antibacterial agents, no epidemiological studies have assessed this risk in the United
States.
Methods: A matched case control study was conducted among a national sample of

patients admitted to all Veterans Affairs facilities between January 1, 2002 and June 1,
2009 to estimate the risk of acute pancreatitis after use of antibacterial agents. A
patient case was defined as patient diagnosed with acute pancreatitis and the control
was defined as a patient diagnosed with myocardial infarction. Conditional logistic
regression was used to compute odds ratios and the 95% confidence interval (CI).
Multivariable models were built to adjust and contiol for the potential clinical
conditions or covariates that might influence acute pancreatitis risk. A stepwise
forward entry method (non-computer generated) was used to develop the final model.
Results: A total of 10,202 patients with acute pancreatitis and 48, 111 patients with

myocardial infarction were identified and entered into the analysis. The mean age for
cases was 55.6 and the mean age for controls was 64.4, and the majority of the study
sample were males (96.5% ). After adjusting for all potential confounders, antibacterial
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agents use was significantly associated with increased risk of developing acute
pancreatitis,. The adjusted odds ratio (AOR) was 1.29 (95% CI 1.18 -1.41).
Conclusion: Among a national cohort of veterans, acute pancreatitis development was

associated with antibacterial agent use.
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Background and Clinical Significance
Acute pancreatitis is an inflammatory disease that affects the pancreas. It
usually affects the pancreatic tissues and in some cases, the inflammation involves the
surrounding tissues. I The amount of inflammation will vary in severity from mild to
severe, to life threatening. Most cases are mild, resolve within days and may only
require a short hospital stay. Severe cases may require hospitalized for days and
sometimes for months due to organ dysfunction. In addition to variety in severity,
acute pancreatitis can occur as a single attack or it can also be recurrent. Acute
pancreatitis is associated with 15-35% mortality rate and the incidence of acute
pancreatitis has increased worldwide.

23
'

In the United States, it is estimated that about

210,000 patients are admitted to the hospital annually for the disease. 2 One study
estimated that an average thirty-nine day hospital stay for acute pancreatitis costs
approximately $100,000 .4
There are several causes of acute pancreatitis. Gallbladder disease and chronic
alcohol consumption are the major causes of acute pancreatitis. Also, hyperlipidemia
(hypertriglyceridemia, ~ 1000 mg/di), inter-abdominal surgical procedures, trauma
from endoscopic retrograde cholangiopancreat_o graphy (ERCP), ischemia, chronic
hypercalcemia, abdominal trauma, infections, autoimmune, hereditary causes,
pancreatic tumor, and medications may increase one's risk for developing acute
pancreatitis.

5 4
-I .

In addition, 25% of the pancreatitis cases occur with unknown

etiology. Is Acute pancreatitis has no specific treatment and requires only supportive
care to prevent complications. I 6 - 18 Acute pancreatitis is a serious disease due to the
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difficulty in diagnosis, limited therapeutic approaches, and poor prognosis with severe
cases.
Medication use is one of the main causes of acute pancreatitis with an
incidence of 0.1-2%. 19 However, this number may not be accurate because
pancreatitis is often misdiagnosed, undiagnosed, and underreported

19

•

Most

medications associated with acute pancreatitis are based on case reports and few
epidemiological studies. Over forty drugs are known to cause acute pancreatitis, they
include; angiotensin converting enzyme inhibitors, estrogen, diuretics, exenatide, and
antipsychotic are some example of drugs that can induce acute pancreatitis. 15 ,20 -23
Some antimicrobial agents have been associated with acute pancreatitis such as
erythromycin, tetracyclines, metronidazole, ertapenem, isoniazide, rifampin and
ampicillin. 24 -28 Most of the medication risk observed are based on case reports, and
there are no known mechanisms to describe how these medications cause acute
pancreatitis. Direct toxic or hypersensitivity reaction and pancreatic duct constriction
are some suggested mechanisms.
The concern over medication, specifically antibacterial agents, causing acute
pancreatitis is important because of the popularity of these agents. Antibacterial
agents are used in clinical practice in both community and hospital settings. There is
therefore a need to understand and determine these potential medical problems risks of
acute pancreatitis associated with antibacterial medications. 23 ' 29
There are currently a series of epidemiological studies that are assessing the
risk of acute pancreatitis with different groups of medication (e.g. statins, ACEis,
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diuretics). These stu d1es
to mcrease.
' ' There are few
studies that assessed the risk of acute pancreatitis, particularly with antibacterial
agents. One study assessed diseases and medications as risk factors of acute
pancreatitis. 7 another study investigated the risk of acute pancreatitis with use of
metronidazole. 31 The aim of the study is to assess and evaluate the risk of acute
pancreatitis with use of antibacterial drugs among a national cohort of patients
admitted to Veterans Affairs (VA) facilities.
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Methods
Study patients. All patients in VA facilities who were diagnosed with acute
pancreatitis in the period between January 1, 2002 and June 1, 2009 were selected in
this retrospective case-control design. Acute pancreatitis cases were identified using
codes from the International Statistical Classification of Diseases and Related Health
Problems, 9th revision (ICD-9-CM). The ICD-9-CM code for acute pancreatitis is
577.00. The study was approved by the Institutional Review Board (IRB) at the
Providence VA and the research office at the University of Rhode Island.

Data sources. The Veterans Health Administration (VHA) administrative
database was utilized to perform this study. There is data for more than 7.9 million
veterans maintained and stored in the Veterans Affairs (VA) medical database, making
it one from the largest medical database in the United States.

32 34
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Additionally The

VA healthcare system includes more than 180,000 medical personnel operating over
164 hospitals, 800 clinics, and 135 nursing homes as of2001. Patients' data in the VA
database is retained on three levels: the local level, the VA Integrated Ser_vices
Networks (VISN) level, and the national level.
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The VA database contains all

medical and pharmacy information for each individual in electronic form. 36 ' 37 All
diseases, procedures, and surgeries in the VA database datasets are coded using the
ICD-9-CM , although some procedures in Medical SAS outpatient datasets are coded
using Current Procedure Terminology (CPT).
disease coding in the VA database.

35 39
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Many studies have validated the

All data required for the study were available

except for weight and height. Weight and height figures were obtained from corporate
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data warehouse (CDW), the national repository containing data from many clinical
and administrative systems within the VHA.

Case definition and selection of control subjects.

Our case patients were

defined as patients who were diagnosed with acute pancreatitis as their primary
diagnosis using ICD-9-CM codes. Only the first diagnosis for acute pancreatitis was
included in patients who had multiple episodes during the study period. For each case
patient, six controls were randomly selected from the population of patients who were
diagnosed with myocardial infarction (ICD-9-CM 410.00-410.92) as their primary
diagnosis and who do not have acute pancreatitis. Controls were matched to cases
based upon month of admission. We selected myocardial infarction as the control
group because these patients present with both acute symptoms and serious outcomes,
similar to acute pancreatitis. For both cases and controls, any patient with infectious
disease as secondary diagnosis was allowed to be included in the study. The date of
admission was defined as the index date.
Patients with peptic ulcer, hemorrhagic ulcer, gastritis, patients who had
ERCP, abdominal trauma, any type of cancer (including pancreatic cancer), human
immunodeficiency virus/acquired immunodefi~iency syndrome "HIVI AIDS", chronic
pancreatitis, bacteremia, alcohol related diseases, gall bladder diseases, and
esophagitis were excluded from the study. Also, patients who were hospitalized during
the 180 days prior to the admission date were excluded.
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Potential covariates. The covariates that were included in the logistic regression
model included age, gender, race, alcohol use (the database indicator entries for
alcohol dependency treatment (BEDSECN=725), alcohol-related DRGs (DRG=433),
ICD-9 codes (305.0, 303.0, VI 1.3, V79.l)), co-morbidities, diabetes, alcohol related
diseases (liver and mental), and inflammatory bowel disease (IBD).
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All prescription

medication data for cases and controls, including drugs that are associated with acute
pancreatitis such as hydrochlorothiazide, prednisone, valproic acid, non-steroidal antiinflammatory drugs (NSAIDs), and azathiopurine were also controlled in the logistic

. mo de 1.24,40-45
regression

Exposure definition. Drug exposure was defined as having received a prescription
of any antimicrobial drug within ninety days prior to the index date. Antimicrobial
medications included the following groups: penicillins, cephalosporins, macrolides,
fluoroquinolones, tetracyclines, clindamycin, metronidazole, nitrofurantoin,
isoniazide, rifampin, pyrazinamide, ethambutol and trimethoprime/sulfamethoxazole
(Table II. I). Drug description variables and the

inte~mediate

product number

(IPNUM) variable were used to identified patient Medications. Only outpatient oral
medications were included in the study.

Statistical Analyses. The main analysis of the current study was to investigate the
association between the risk of acute pancreatitis and exposure to antibacterial
medications. A chi-square test or Fisher exact tests were used to analyze the
categorical data while a student's t-test or Mann Whitney test were used to analyze the
Continuous variables for both demographic and clinical data. Odds ratio and their 95%

confidence interval (CI) were derived from the conditional logistic regression.
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Initially, the potential clinical covariates that would be entered the multivariable
model were selected based on bivariate analyses. Covariates with differences of 10%
between the cases and controls were included in the multivariable model. Then, the
final model was built using stepwise forward entry method (non-computer generated).
At each time, a covariate was added, and ifthe estimated coefficient (B) of
antimicrobial exposure changed by more than 10%, this covariate was kept in the final
model. Furthermore, two-way and three-way interactions were assessed. At each step,
an interaction term was added to the model, and if the estimated coefficient (B) of
antimicrobial exposure changed by more than 10%, the interaction term was kept in
the model. Multicollinearity was assessed using variance inflation factor (VIF). A
cutoff of2.5 for VIF was used to indicate the presence of multicollinearity. All
statistical tests were conducted with a two-tailed alpha of 0.05. All analyses were
conducted using SAS® version 9 .1.3 (SAS® Institute, Inc, Cary, NC).
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Results
Between January 1, 2002 and June 1, 2009, a total of23,899 patients were
identified with a primary diagnosis of acute pancreatitis. Inclusion and exclusion
criterion for the study were applied to these patients. Among these cases, patients with
of any type of cancer, including pancreatic cancer, (n=899), chronic pancreatitis (n=
2,861), HIV or AIDS (n=369), bacteremia (n=578), ERCP (n=295), abdominal injury
(n=9), alcohol related diseases (n=l,842), .gall bladder or biliary diseases (n=3,528),
peptic/hemorrhagic ulcer or gastritis (n=376) and esophagitis (n=2,222) were
excluded. In addition, patients who were admitted to the hospital for any medical
conditions in the previous 180 days prior to the index date (n=718) were excluded
from the study. After application of the exclusion criteria, 10,202 patients were
eligible for the analyses.
The Distribution of demographic and clinical characteristics of the cases
(patients with acute pancreatitis) and the controls (patients with acute myocardial
infarction) can be found in Table 11.2. Patients in the case group were younger (mean
age 55.6) than the patients in the control group (mean age 64.4). The majority of our
population was male. In general, our sample's racial breakdown was mainly white
non-Hispanic (58%), followed by black (18.5%). The control group had a higher
percentage of white non-Hispanic (63.9%) compared to the case group (52.3%). The
case group had a higher percentage of black patients (24.3%) compared to the control
group (12.6%). Also, there were more native Americans in the case group (0.50%)
compared to the control group (0.30%). There was no difference among Asian and
Hispanic races.
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The case group differed from the control group in alcohol abuse,
hypertriglyceridemia, hypercalcemia, and IBD, while there was no difference in other
covariates such as diabetes mellitus and use of comparable prescription medications
( Table II.2).
Fluoroquinolones antibiotics were the most used antibiotics among case group
patients and control group patients (2.8% and 2.9 respectively), followed by penicillin
(2.7% and 2.3%, respectively). Nitrofurantoin (0.03 and 0.08, respectively) and antituberculoses medication (0.04 and 0.05, respectively) were the lowest utilized
antibiotics by the study population. Use of sulfamethoxazole/trimethoprim was equal
among case group patients and control group patients (0.9%).
Odds ratios (OR) and the 95% confidence intervals (CI) were computed from
the adjusted conditional logistic regression model (Table II.3 & Table II.4). After
controlling for all of the potential confounders in the multivariable model, there was a
statistically significant association between antibacterial use and developing acute
pancreatitis. The adjusted odds ratio (AOR) was 1.29 (95% CI 1.18 -1.41 ), suggesting
that patients with acute pancreatitis are 1.29 times more likely to have been exposed to
antibacterial agents than control group.
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Discussion
The current study utilized a matched case control study design using the
national Veterans' Affairs database to investigate the association between the use of
antibacterial drugs and acute pancreatitis development. To current knowledge, this is
the first epidemiological study to assess this association for all oral antibacterial agents
as one group in the United States.
There is a known risk with metronidazole use and the risk of acute pancreatitis.
Previous investigations found an association with metronidazole use within thirty days
prior to index date (AOR was 3 .0, 95% CI 1.4-6.6).

31

Furthermore, they found that

patients who used metronidazole with proton pump inhibitors to treat peptic ulcers due
to helicobacter pylori and/or using amoxicillin, macrolides, or tetracycline within
thirty days prior to index date were at risk of developing acute pancreatitis (AOR was
8.3, 95% CI 2.6-26.4).
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However, it is important to note that the increased risk in

patients with peptic ulcers could be due other confounding factors.
Investigators in

Swede~

used a population case control study to investigate

disease and medication risk factors for acute pancreatitis. The risk of using systemic
antibacterial agents was evaluated in addition to several other medication classes.
After adjusting all the potential confounders, the AOR was 1.9, 95% CI 1.1-3.2,
indicating that systemic antibacterial agents were associated with acute pancreatitis
development. 7

Numerous case reports have linked acute pancreatitis with several antibacterial
agents. Penicillins, fluoroquinolones, macrolides, tetracyclines, metronidazole, and
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sulfamethoxazole-trimethoprim are some of the antibacterial agents that have case
..
reports associating them wit. h acute pancreat1tls.

28 46-56

'

. . o f t hese case
T he maJonty

reports found that patients with acute pancreatitis induced by antibacterial agents were
middle aged. This data is consistent with our results. In this study, the patients with
acute pancreatitis were younger than the control group. Newer antibacterial agents
..
also have generated case reports o f acute pancreatitis.

27 57

'

Another report described a case of acute pancreatitis that resulted from using
tigecycline, a compound related to tetracyclines.
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The patient was a thirty five year

old male, who had undergone surgery to remove tissue that was infected with
Enterobacter cloacae. He was initially given tigecycline, imipenem and amikacin.

After thirteen days of treatment, he developed upper abdominal pain, and his lipase
level was elevated. He was subsequently diagnosed with acute pancreatitis.
Tigecycline and amikacin were stopped; the patient's lipase level then started to
decrease and he was no longer experiencing any abdominal pain. After five months,
his lab tests returned to baseline.
The incidence of drug induced acute pancreatitis is between 0.1-2%.19
Although the exact mechanism of antibacterial induced acute pancreatitis is still not
known, several mechanisms were suggested for different antibacterial groups. The
mechanisms for tetracyclines to be associated with acute pancreatitis were suggested
as: (1) accumulation of toxic metabolite, (2) hypertriglycerdemia induced by
tetracyclines, and (3) increased concentration of tetracyclines in the biliary duct. It is
theorized that the formation and accumulation of a toxic tetracycline metabolite is
responsible for causing acute pancreatitis, although no metabolite has been identified
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yet.
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Furthermore, tetracyclines inhibit protein synthesis, which could lead to a build

up of defective protein within the hepatocyte and inhibit triglyceride release to the
liver. This process leads to increased triglyceride levels causing acute pancreatitis.
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The other possible mechanism is that the high concentration of tetracyclines in the bile
is the major reason for tetracyclines induced acute pancreatitis.
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Minocycline

concentration in bile was found to be ten times the concurrent serum concentration.
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Also, the concentration of doxycycline and tetracycline in the bile reached up to eight
times and 1Otimes the serum concentration, respectively.

6

°Further, tigecycline

biliary elimination rate is 500 times the plasma rate, which could be a major reason for
. .

acute pancreatlt1s.
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An rational for acute pancreatitis and macrolides use has been postulated. It is
suggested that macrolides cause acute pancreatitis through their prokinetic property.
They stimulate contraction of gastrointestinal tract, resulting in spasms and increased
pressure of the sphincter of Oddi and bile reflux.

7 49 61 63
' ' -

Some medications diffuse

directly to the pancreas, leading to acute pancreatitis by direct toxic effect through the
release of free radicals like in the case of metronidazole.

19 28 64 65
' ' '

Immune mediated

reaction, hypersensitivity reaction, and toxic effect are suggested mechanisms of drug
induced acute pancreatitis in several antibiotics such as sulfonamides, anti tuberculosis
medications, and nitrofurantoin.

7 19 66 67
' , ,

Generally, middle-aged patients are at greater

risk of developing acute pancreatitis than elderly patients and black patients at greater
risk than white patients, which are both consistent with this study' s results.
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Antibacterial agents are considered an integral part in the therapeutic plan for
acute pancreatitis to prevent the complications of acute pancreatitis such as
45

bacteremia. 1 However, using antibacterial agents in acute pancreatitis still remains
controversial.
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Using antibacterial agents in patients with acute pancreatitis is based

upon results from a randomized clinical trial that found administration of imipenem
reduced infectious complications.
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However, a recent randomized clinical trial that

compared ciprofloxacin plus metronidazole to placebo and found there is no difference
in outcomes between the two groups.
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Therefore, routine use of prophylactic

antibiotics in acute pancreatitis is not recommended until the patient develops an
infection. This study's results also support these recommendations since it was found
that antibacterial agents were associated with acute pancreatitis. Thus, unnecessarily
giving the patient with acute pancreatitis prophylactic antibacterial agents to prevent
infections should be avoided since these medications were associated with acute
pancreatitis development.
Several indicators were used to find patients with alcohol use among the cases
and controls. These indicators included ICD-9 codes, alcohol dependency treatment
indicators, and alcohol-related DRGs. This variable in the model was determined
using the previous indicators. The Department of Veterans Affairs (VA) requires an
annual alcohol screening for any VA patient. 72 In 2000, the screening rate was 85%,
which is considering a high rate. 73 To continue this screening program of VA patients,
the Veterans Health Administration (VHA) implemented an evidence-based alcohol
screening program. A study done in 2006 found that the screening rate of alcohol
misuse was 93%. 74 Additionally, the Computerized Patient Record System (CPRS) at
the VA has a reminder for the clinician to perform an AUDIT- consumption (AUDITC) questionnaire for alcohol misuse. 74 These programs were established for the
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purpose of screening as well as providing counseling to patients with alcohol misuse.
Based on these programs, it was determined that virtually all VA patients
werescreened for alcohol use.
In any observational study, the potential of confounding by indication should
be evaluated. Confounding by indication is when patients with severe diseases and
comorbidities were more likely to received antibacterial agents than those with
moderate diseases. In this study, patients with major risk factors (e.g. patients with
gall bladder diseases and alcohol related disease) and those who had been admitted in
the hospital during the last six months prior to the index date were excluded from the
study. Additionally, the remaining variables were controlled in the regression model.
This study has several strengths. The use of a very large database provides data
for a large sample size. This allowed all exclusion and inclusion criteria that have been
identified to be applied. Additionally, many potential confounders such as
hypertriglycerdemia, alcohol abuse, and other confounders were controlled.
While this study has several strengths, it also has potential limitations. As with
all administrative databases, the pharmacy data describes the dispensed antibacterial
agents, but it is not known if the patients were actually administered their medications.
Also, the validity of acute pancreatitis diagnosis in the VA databases was not
evaluated and assessed in an epidemiological study. The diagnosis of acute
pancreatitis may be underestimated and not classified in mild cases. 75 additionally,
incideince of drug induced acute pancreatitis is not accurate because it is often
misdiagnosed, undiagnosed and underreporting. 19 Furthermore, as with most of
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administrative databases, missing data and missing codes are always potential
problems. In this study, initial plans included incorporating BMI in the analysis.
Weight and height were used to calculate BMI, but up to 48% of the height and weight
values were missing. Therefore, it was decided not to include BMI in this study.
Additionally, the majority of the population in the study are male veterans, therefore
the results may not be generalized to women and non-veteran patients. Finally, as
with other observational studies, residual confounding cannot be completely excluded.
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Conclusion
In conclusion, it was found that antibacterial medications were significantly
associated with increased risk of acute pancreatitis among a large national sample of
veterans. In addition, further studies are required to confirm this conclusion and to
understand the underlying mechanism of this association. Further research is also
required to investigate the role of individual antibacterial agent is in the development
of acute pancreatitis.
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Table 11.1: List of antibacterial agents including in this study.
Antibacterial group
Penicillin

Drug name
Penicillin VK
Amo xic illin
Amoxic ii lin/c la vu lnate
Cloxacillin

Cephalosporin

Cephalexin
Cephradine
Cefaclor
Cefuroxime
Cefprozil
Cefixime

Macrolide

Erythromycin
Azithromycin
Erythromycin

Fluoroquinolone

Ciprofloxacin
Levofloxacin
Moxifloxacin

Tetracycline

Tetracycline
Oxytetracycline
Doxycycline
Minocycline

Lincosamides

Clindamycin

Anti-tuberculosis

Isoniazide
Rifampin
Pyrazinamide
Ethambutol

Nitroimidazole

Metronidazo le

Miscellaneous

Trimethorpim/Sulfamethoxazole
Nitro furanto in
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Table 11.2: Demographic and clinical characteristics among patients with acute
ancreatitis (cases) and patients with myocardial infarction (controls) in the
~eterans Affair database (Jan 2002-June 2009).
p

Age, mean (SD)
Gender (male%)
Race
White
Black
Asian
Hispanic
Native American
Unknown

Cases (N= I 0,202)
55.6 (12.3)
95.4%

Controls (N=48, 111)
64.4 (11.7)
97.9%

5,336 (52.3%)
2,479 (24.3%)
50 (0.49%)
335 (3.3%)
51 (0.50%)
1,951 (19%)

30,723 (63.9%)
6,052 (12.6%)
218 (0.45%)
1,645 (3.4%)
149 (0.30%)
9,351 (19.3%)

Alco ho 1abuse*

3,502 (34.3%)

2,247 (4.7%)

<0.01

Co morbidities
Diabetes Mellitus
Hypertriglyceridemia
Hypercalcemia
Inflammatory Bowel
Diseases (IBD)

3,545 (34.8%)
970 (9.5%)
99 (0.97%)
97 (0.95%)

17,656 (36.7%)
1,033 (2.2%)
112 (0.23%)
137 (0.28%)

<0.01
<0.01
<0.01
<0.01

<0.01
<0.01

<0.01

Prescription
Medications§
Prednisone
161 (1.6%)
952 (1.9%)
0.01
Valproicacid
18(0.18%)
46(0.10%)
0.03
Azathioprine
13 (0.13%)
38 (0.08%)
0.13
SSRI
791 (7.8%)
. 3,044 (6.3%)
<0 .01
NSAID's
781 (7.66%)
3,693 (7.68%)
0.94
Hydrochlorothiazide
783 ·(7.67%)
3,649 (7.58%)
0.75
Antifungal
19 (0.19%)
48 (0.10%)
0.02
*Based on ICD-9-CM, alcohol-related DRGs and alcohol dependency indicator
§Medications known to cause acute pancreatitis
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Tables II.3: The results of multivariable model showing the risk of acute
pancreatitis associated with antibacterial agents used.
Variable

Crude Odds Ratio
(95%CI)

Adjusted OR (95% CI)*

Antibacterial agents

1.18 (1.09-1.29)

1.29 (1.18-1.41)

Age

0.94 (0.93-0.94)

0.96 (0.95-0.97)

Gender$

2.14 ( 1.87-2.4 7)

2.10 ( 1.83-2.41)

Black

1.83 (1.71-1.95)

1.58 (1.47-1.70)

Hispanic

1.17 (1.02-1.35)

1.16 (0.99-1.35)

Asian

1.48 (1.04-2.12)

1.62 (1.13-2.33)

Native American

1.55 (1.08-2.24)

1.33 (0.89-1.98)

Unknown

1.18 ( 1.11-1.27)

1.18 ( 1.11-1.27)

Alcohol abuse

7.32 (6.83-7.86)

7.10 (6.61-7.61)

SSRI

1.18 ( 1.08-1.30)

1.30 (1.18-1.44)

Race§

* Adjusted for all potential confounders in the table
$ The reference group is male gender
§ The reference group is white race
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Tables II.4 Estimate of the risk of acute pancreatitis among users of antibacterial
agents in a population of veterans.

Antibacterial
agents

Cases (n=l0,202)

Controls (n=48,lll)

(%)

(%)

1007 (9.87%)

4485 (9.32%)

*Adjusted for all potential confounders in the table 11.3
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Adjusted OR
(95%CI)*
1.29 (1.18- 1.41)
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CHAPTER III
Review the healthcare databases in United States and European countries that
are commonly utilized in conducting epidemiologic research
This manuscript will be submitted to the Pharmacoepidemiology and Drug Safety
(PDS) journal
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Abstract
Medical databases play a major role in conducting pharmacoepidemiological
studies. They are used to perform descriptive and observational studies. Having an
ideal database is challenging and not easy to find, especially in countries lacking a
universal healthcare system. Countries with a social healthcare system have the ideal
environment to have an ideal medical database. There are many medical databases in
the U.S as well as Europe and other countries worldwide. Each database has its own
structure with unique variables included in that database. Also, each database has its
own strengths and limitations, giving each one the ability to answer different research
questions. In this review, four databases will be investigated. Two databases from the
U.S., the NIS-HCUP database and the VA database, and two databases from Europe,
the THIN database and the Norwegian databases are included in this review. In
addition to providing detailed information on each database, the purpose of this review
is to explain the differences between the U.S databases and Europe databases and the
benefit of having a social healthcare system in the competence and validity of these
databases.
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Introduction
Computerized healthcare database or medical databases contain a variety of
information that can be used for descriptive and observational studies. These medical
databases provide sufficient information to answer research questions related to
health, including diseases, drug therapies, and beneficial and adverse effects to drug
therapies. 1 The strengths and weaknesses of each database vary and are limited to the
data collected and the quality of the input.
Healthcare databases are divided into medical record databases and
administrative databases. Various healthcare databases are available in United States
(U.S.) as well as in other countries. 2 The Veterans Affairs (VA) database, Group
Health Cooperative of Puget Sound, Medicaid, and Kaiser Permanente Medical Care
Programs are some examples of healthcare databases in the U.S. In Europe, there is
generally a universal healthcare system, and large collective databases making for are
an ideal database to study where complete healthcare information is needed.
The ideal healthcare database would include inpatient care, outpatient care,
emergency care, mental health care, laboratory tests, radiological tests, prescribed and
over the counter (OTC) medications, and alternative therapies. 2' 3 In addition to
medical information, the availability of economic data (direct and indirect medical
costs) increases the capability of the database, especially when
pharmacoepidemiologic and pharmacoeconomic studies are being performed.
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With a wide variety of healthcare databases available to the researcher, many
research questions can be answered by comparing the research question to the
different components of the various databases.
We conducted a comprehensive review of four different globally available
databases. We will describe each database, identify the advantages and disadvantages,
and the type of research questions that can be answered using the database. Included
in this review are two databases from the United States (The Nationwide Inpatient
Sample-Healthcare Cost and Utilization Project (NIS-HCUP), and the Veterans'
Affairs (VA) Medical Database), the Health Improvement Network (THIN) from the
United Kingdom, and the Norwegian medical databases. A lack of publically
available resources on the Canadian and Japanese medical databases limited our
attempt to critique them in this review.
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The Nationwide Inpatient Sample-Healthcare Cost and Utilization
Project (NIS-HCUP)
The largest all-payer inpatient care database in the United States is said to be
the Nationwide Inpatient Sample (NIS) medical database. It was created under the
Healthcare Cost and Utilization Project (HCUP), which is a large family of healthcare
databases. 4 ' 5 The Kids' Inpatient Database, the State Inpatient Databases, the State
Ambulatory Surgery Databases and the State Emergency Department Databases are
also members in HCUP databases. The HCUP is federally supported and sponsored
by the Agency for Healthcare Research and Quality (AHRQ). 6 The NIS database
released its first dataset in 1988, which at that time, included information from eight
states. State participation increased considerably and in 2007, AHRQ collected data
from 1,044 hospitals in forty states. 4 This Nationwide Inpatient Sample represents
about a 20% stratified sample of all patients admitted to community hospitals in the
U.S annually and in 2007, 90% of all hospital discharges in the United States were
included in the sampling frame ofNIS. To establish a sample that represents the
hospitalization in United States, ·the hospitals selected in NIS were stratified based on
five characteristics: U.S. geographic region, bed size, teaching status, rural or urban
location, and ownership. 5 ' 7 ' 8 Community hospitals are defined by the American
Hospital Association (AHA) as all public, non-federal, short-term hospitals where the
average length of stay is less than 30 days. These hospitals have identifiers that
connect to the AHA annual survey database and county identifiers that permit linkages
to the Area Resource File. 5 This database has been used by many researchers to
identify and analyze different national healthcare trends, including, healthcare
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utilization, charges, quality, access, and outcomes.

9 11
-

Since 1988 all datasets are

publicly available to conduct research projects and to analyze information regarding
different types of diseases and medical conditions as well as other aspects of health.
One of the main advantages ofNIS is the ability to run an analysis of trends over
time.4 In 1988, the estimated number of discharges was slightly over 35 million
observations in comparison to 39 million discharges in 2005. This database continues
to grow. NIS contains a significant amount of data, including information that cannot
be studied in other medical databases, specifically, it contains information on rare
diseases such as autoimmune hepatitis; uncommon treatments such as organ
transplantation; and special groups of patients, such as the uninsured patients. 4' 12
Essential elements of NIS

The information included in NIS consists of patient hospitalization admission
and discharge information. NIS has more than 100 clinical and nonclinical data
components for each hospital admission. These elements include primary and
secondary diagnoses, primary and secondary procedures, admission source, discharge
destination, payment source, and hospital characteristics (hospital size and teaching
status) (Tables III.I). 4'8 Descriptive data regarding patient demographics, include
age, gender, race, and the median income for each area (via zip code) is also included.
In addition, other elements have been added, such as all patient refined
diagnosis related groups (APR-DRGs), all payer Severity-Adjusted Diagnosis related
groups (APS-DRGs), disease staging, and AHRQ co-morbidity indicators. 4 The
typical discharge abstract includes all clinical and resource use information, which are
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all protected to safeguard the privacy of the individual patient, physician, and hospital.
The confidentiality of individuals' information is achieved by using two procedures:
(I) no patient identifiers are included in the discharge abstracts or other parts of the
database, and (2) researchers or users of the database agree, through data use
agreement, to use the data for research and statistical purposes without any attempt to
identify individuals.

4 6 13
' '

Nevertheless, NIS excludes any data elements that could

directly or indirectly lead to the identification of individuals. The identity of some
institutions can be released when the data resources of these institutions are available
to the public or there is an agreement to release the information.

4 3 4
,l ,1

Using NIS

Like most U.S medical databases, all diagnoses in NIS database are recorded
using administrative data. The NIS uses the International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) and up to 15 diagnoses are
recoded. 8' 15 To enable researchers to perform a study that spans multiple years, NIS
created NIS- trends supplemental files (NIS-Trends) . .Jt is recommended to include
only years after 1993 to perform ~tudy with trend analysis. 12 Since NIS is a uniform,
multiple-year and multi-state database, it could be used to explore different topics such
as quality of care, medical treatment effectiveness, or healthcare cost (Table III.2).
Furthermore, it is useful for answering research questions related to patient outcomes,
cost of hospital care provided to specific populations, cost of treating different types of
diseases, and other salient healthcare questions (Table IIl.3).
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4 16
'

The diversity of the NIS database and the extensive data available attracts
many profit and non-profit organizations' researchers to utilize this data source. State
and federal government agencies, healthcare consultants, hospitals, and healthcare
systems are the main users of NIS (Table III.4 ).

4

Access to NIS database
NIS datasets can be accessed through the HCUP central distributer
(http://wwvv.hcup-us.ahrq.gov/nisovervicw ..i.fill ). New data are released each year.

This can be downloaded to a desktop computer with CD-ROM reader, and can be run
using statistical software packages such as Statistical Analysis System (SAS)®,
Statistical Package for the Social Sciences (SPSS)® and Stata®. To obtain the datasets,
a NIS Data Use Agreement must be signed to guarantee the privacy and security of
individual information. In addition, a dataset charge is assessed, which is considerable
inexpensive in comparison to the real value of the datasets. The dataset for year 2006
may cost $200, which includes a set of two CD-RO Ms and accompanying
documentation. HCUP supports NIS' s users with "HCUP User Support" to answer
questions through a toll free nu~ber and via email. 4
Advantages and limitation of the NIS database
NIS is the largest all-payer inpatient database in the United States 5'6 It is
unique because it has data documentation containing many variables for a large
number of patients. It started in 1988, making it a useful database to perform analysis
of trends over time. It also covers thirty eight states, and it samples 90% of all hospital
discharges in the United States, allowing for appropriate representative of the US
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population. Other reasons that make NIS a valuable database include its ability to
study rare diseases due to the large number of documented patients and to perform
studies in different areas such as healthcare cost, epidemiology of diseases, access to
care, quality of care, and health outcomes with the information regarding different
sources of insurance (e.g. Medicaid, Medicare, private insurance companies) and
uninsured patients. On the other hand, NIS has some limitations. One major limitation
is the lack of pharmacy data therefore, performing studies related to medications is not
possible. 17 In addition, data outside the hospital system (i.e. outpatient physician
office) is not available. NIS database does not include data on alcoholism and drugs
abuse and the data on race and ethnicity is incomplete in some states (Table III.5).
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5

Veterans Affairs Medical Database
The Veteran Health Administration (VHA) is a part of the United States
Department of Veterans Affairs (VA). VHA services began in 1777 when the first
federal hospital was built in Pittsburgh.
services to military personnel.

19

18

The hospital originally offered surgical

Between 1916 and 1945, the VA hospitals broadened

their medical expertise and the number of hospitals increased.

19 20 21

After 1980, the

VA expanded into a powerful health system in the United States by opening and
operating numerous hospitals, outpatient clinics, medical centers, and long-term health
care facilities across the country. Currently, the VA operates 163 medical centers, 909
ambulatory care and community-based outpatient clinics, 232 Veterans Centers, 137
nursing homes, 108 comprehensive home-care programs, and 4 7 residential
rehabilitation treatment programs, providing high quality medical, surgical, and
rehabilitative care.

22 23
'

The Veterans Affairs (VA) medical database is considered from the largest
medical databases in the United States.

24 26
-

It contains information for more than

seven million veterans and their dependents. 22 ' 27 The large number of patients in the
VA medical database makes it a very unique database that can address many research
questions.
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vA structure and information center
The VA database maintains patients' data on three tiers: the local level, the VA
Integrated Service Networks (VISN) level, and the national level. The local level
refers to the patient data in the Veterans Health Information Systems and Technology
Architecture (VistA) system, which is usually one medical facility. The second level is
VISN level, whereby VHA structured and grouped medical facilities across the
country are divided into 21 VISN s. VISN s are classified based on their geographical
area. The VISN database contains data from multiple VistA giving it more data than
the local level but less data than the national level. For the purpose ofresearch in a
specific health or medical field, the appropriate choice would be the national level
database. The national level is a combination all local facilities stored in a central
location. National data is maintained by The National Data Systems (NDS) Division
oflnformation Assurance, VHA Office oflnformation.

28

Housed in Austin, Texas,

the Austin Information Technology Center (AITC) is the central location for the
national level database, and the V A's centralized computer-processing center.

28 29
,

The VA Information Resource Center (VIReC) is responsible for assisting
researchers on how to use the database and giving full information about the datasets
in AITC. In addition, VIReC provides detailed information in different areas such as
requesting access to the datasets, programming tips, and how to connect to the Austin
mainframe to run analyses.

14 30
,

All medical variables are described in detail and

determined in which file these variables are available.
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Data structure
There are different data sources within the VA database that can be utilized by
researchers to conduct their studies (Table III.6).

31 32
'

Each separate data source has

different types of information that helps to conduct several types of studies (medical
and non-medical). This review will focus on VA Decision Support System (DSS)
(production data and National Data Extracts) and the VHA Medical SAS® Datasets
because they are the most utilized datasets.

31

The VHA Medical SAS Datasets
The VHA Medical SAS® Datasets include all of the healthcare utilization
information for veterans who have been treated in VA hospitals or other treatment
facilities. These datasets include information on non-veterans such as VA employees
and research participants.

33

These data are extracted from national patient care

database (NPCD) and provided in SAS® format for each fiscal year (Oct 1 - Sep 30).
All VHA Medical SAS® Datasets are stored on an IBM mainframe computer at the
Austin Information Technology Center and maintained by the VHA Office of
Information at the same center. Patient information transmitted from the local VistA to
the Austin Automation Center (AAC), where it is converted to SAS format.
The VHA Medical SAS® datasets include two major datasets: Medical SAS®
Inpatient Datasets and Medical SAS® Outpatient Datasets. 33 '34
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Medical SAS® Inpatient Datasets
The Medical SAS® Inpatient Datasets have four main categories for inpatient
admissions: acute care, extended care, observation care, and non-VA care. Within
each type ofcare, there are four datasets: main, bed section, procedure, and surgery.
All the categories have these four datasets (main section, bed section, procedure
section and surgery section) except observation care, which has only main, bed section
and procedure. The definitions of these datasets are illustrated in Table III. 7.

4 33

t ,

The main section dataset includes most of the important inpatient variables,
such as demographic data, socioeconomic data, and clinical data. It includes one
principal diagnosis, or the condition causing the patient admission to the hospital and
up to twelve secondary diagnoses. Other variables included in the datasets are date of
admission and date of discharge (time, date, month and year), date of death, drug
related group (DRG), race , ethnicity, source of admission, and VISN number. Bed
section dataset refers to the patient care that is provided by treating specialty during
the inpatient stay and does not refer to a physical location of care, it has variables
related to the bed section, such as admission and discharge date and DRG for bed
section. It also has one primary diagnosis or the main reason for the full stay in bed
section, and up to four secondary diagnoses. It has very unique variables not contained
in other datasets, including a drug abuse indicator and a suicide indicator. The
procedure dataset contains data for each procedure performed during the inpatient
stay. It includes up to five procedure codes for the diagnosis, admission, and discharge
dates and other procedure variables. The surgery datasets contain up to five surgery
codes for the diagnoses, date of admission and discharge, and other variables related to
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surgery. A Scrambled Social Security Number (SCRSSN) is used as an Identification
Number (ID) for each patient to protect patient privacy. All of these datasets can be
combined using SCRSSN.

35

Medical SAS® Outpatient Datasets
The Medical SAS® Outpatient Datasets include patient information that is
available in the VHA's ambulatory care. This data is collected and stored at the Austin
Information Technology Center (AITC). This data is transferred from each local
VistA and organized "electronically" at AITC. This data is updated by AITC every
two weeks. Medical SAS® Outpatient Datasets include three datasets; visit dataset,
event dataset, and inpatient encounter datasets. The visit dataset was created in 1980
and contains information about each day's outpatient care encounter. It contains all
patient's demographic data and clinic stop codes (up to fifteen codes) for a day's care.
Any patient who has been seen in any of the VA outpatient clinics has a record. The
event dataset was created in 1997 and contains information for each ambulatory clinic
stop by a patient during a day's outpatient care. The event dataset is larger than the
visit dataset in the number of va~iables and has no limited number of clinic stops. It
has information regarding patients' demographic data and procedures and surgery
performed in an outpatient setting. There is one primary diagnosis and nine secondary
diagnoses. The inpatient encounters dataset includes information about each
outpatient encounter during an inpatient stay. It is similar to the event dataset,
although it does have more variables. It is the only dataset among outpatient datasets
that contains the admission date and discharge date.
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30 36
'

11

Coding system
All diseases, procedures, and surgeries in the Medical SAS® Inpatient Datasets
are coded using ICD-9-CM. The ICD-9-CM is also used to code diseases and
surgeries in Medical SAS® Outpatient Dataset while Current Procedure Terminology
(CPT) is used to code procedures. Smoking and substance abuse are very important
issues in any dataset; there are different sources of coding for these variables, using
ICD-9-CM in Medical inpatient dataset "in main and bed section" to find the patients
who are smoker or substance abuser. In addition there is a substance abuse indicator in
bed section. In medical outpatient datasets, these variables can be captured using ICD9-CM in Visit dataset while clinic stop coded can be used in both Event and Inpatient
Encounter datasets. 35 -37
VHA Decision Support System (DSS)
The VHA Decision Support System (DSS) is a national system using specific
software to integrate clinical and financial data for both inpatient and outpatient care.
This software transports the patient data from three main resources: VistA, NPCD, and
Patient Treatment File (PTF). VHA DSS was created in 1994 and completed in 1999.
It has three levels of aggregation: VHA DSS Production databases, VHA DSS Report

summary, and VHA DSS National Data Extracts (NDE).
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38

VHA DSS Production Databases
DSS production database contains data regarding costs; clinical information,
such as resource utilization and patient outcomes; and workload captured over
different levels (e.g. encounter, day and laboratory results). The software also has
tools to help the researcher or the team staffs to perform a variety of analyses. The
researcher can study a pattern of care for inpatient stay, following a cohort of patients
with a specific outcome over time; study a specific topic related to laboratory results;

. de o f s1m1
. ·1 ar researc h questions.
.
37 38
or a multitu
'
VHA DSS Report summary
DSS report summaries are provided by the VISN Supported Service Center
(VSSC). These reports are made using National DSS SAS Datasets and can be
accessed and downloaded through the VA intranet website. Hundreds of reports are
available in the VA intranet, such as average patient cost, costs by DRGs, and other
reports. 37
VHA DSS National Data Extracts (NDE)
VHA DSS NDE has been created by co-working between the DSS Program
Office and the VHA VSSC selected database fields. These NDE datasets are created in
SAS format and each dataset is released in January for the fiscal year that ends on
September 30th. DSS SAS NDE are stored and housed in AAC (Table III.8).

37 38
'

In this review, Pharmacy National Data Extracts, Laboratory National Data
Extracts, and Laboratory Result National Data Extracts will be discussed in detail.
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The Radiology National Data Extracts are very similar to the datasets that are included
in the review; it has the same sources, structure, and some similar variables.

Pharmacy National Data Extracts
Pharmacy datasets are often the largest component of the database, forcing
them to be separated based on VISN. In 2002 and 2003, the pharmacy datasets were
divided based on group of VISNs (e.g. VISN 1 - 5 Inpatient, VISN 6 - 10 inpatient,
VISN 11-16, VISN 17-22 and the same arrangement for outpatient files), but starting
in 2004, these datasets were divided based on each individual VISN combining both
inpatient and outpatient (e.g. VISN 1, VISN 2 consecutively through VISN 23). These
datasets include records of every prescription filled by a VA outpatient pharmacy or
by the Consolidated Mail Outpatient Pharmacy (CMOP), each inpatient unit dose
order, and every IV solution that is dispensed from a pharmacy. Ward stock
medications, Bar Code Medication Administration (BCMA) packages, and controlled
substances are not included in these datasets.

37 39
,

Different sources, including the VistA Pharmacy Prescription File, the Unit
Dose Extract File, and the IV Extract File, are used to collect the medication data.
DSS files are the source for all information pertaining to costs. Patient demographics
are collected from patient's file, and encounter information is collected by VistA
Patient Care Encounter file (PCE).

37

In addition to pharmacy data, both the direct cost (e.g. drug cost) and the
indirect cost (e.g. the indirect costs of medical center) are included in the dataset.
Other datasets inside NDE, including the Outpatient Extract, Inpatient Discharge
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Extract, and Inpatient Treating Specialty Extract, have some pharmacy cost
information. This additional information is one of the major strengths of these datasets
as it is not available in many non-VA databases.

40 41
'

In the dataset, there is one section for inpatient encounter records and another
section for outpatient encounter records. The inpatient encounter records contain all
inpatient pharmacy prescription starting from admission until discharge. The
outpatient encounter records contain all outpatient pharmacy prescriptions. In these
datasets, there are more than thirty seven variables that include demographic,
medication, and cost data. Most of these variables use a code unique for pharmacy
datasets, such as VA_Class, Intermediate Product Number (IPNUM), INOUT.
IPNUM variable refers to the DSS product number that is assigned to each drug.
IPNUM can be used to identify a patient's medications and the drug description
variable (DRUGDESC). These variables are updated every time for easy use
(Table III.9).

37 42
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These datasets are very useful to conduct many researches because they have
all of the important medication information, including the name of the drug. National
Drug Code (NDC), formulary indicator (formulary Vs non-formulary), fill date
(service date), quantity dispensed, all cost types, patient SCRSSN, age, gender,
provider identification number , and provider treating specialty. 37 ' 43
The DSS Pharmacy NDEs are a major source for researchers to conduct
research requiring information on medications. They are not the only datasets that
include medication information, but they are the largest.
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Other pharmacy resources
In addition to the DSS Pharmacy National Data Extract, other important
resources include VISTA system, DSS National Pharmacy Extract "Planned" datasets,
and the Pharmacy Benefits Management (PBM) group.

41 44
,

Laboratory National Data Extracts and Laboratory Results National Data
Extracts
Laboratory National Data Extracts and laboratory results National Data
Extracts were created in 2002 and 2000, respectively. As in Pharmacy NDEs, these
datasets have been divided based on groups ofVISNs until 2003. After 2003, these
datasets were produced for each individual VISN (e.g. VISNl ... VISN23). 37
Laboratory ND Es include all laboratory workload data and the cost of these laboratory
tests. The laboratory tests and laboratory results are entered at the individual level for
both inpatient and outpatient encounters.

43

The major source of these extracts is the DSS: DSS records all patient entries
in the VistA lab package, which are then transported to laboratory and laboratory
result datasets. Each year, DSS posts more tests in the datasets, and by the 2008
fiscal year, these datasets included seventy one of the most commonly ordered tests.
The result of these seventy one laboratory tests are extracted from the laboratory result
NDEs.

37 43
'

VistA system is not the only source for laboratory and laboratory results

datasets. Other sources are used to collect demographic, clinical, and economic
information. These resources are patient file (#2) , the referral patient file (#67), VistA
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patient movement file (#405), VistA patient care encounter file, and DSS processes
(Table III.10).

43

Both datasets have very useful variables that can be used to obtain data related
to laboratory tests and laboratory results, including date of admission, date of
discharge, time collection of the specimen, date of service, and other variables. Each
dataset has its own unique variables, for instance cost data is only found in laboratory
datasets. These cost variables include ACT_COST "actual total cost," LAB_VD
"laboratory variable direct costs," LAB_FD "laboratory fixed direct costs," and
LAB _FI "laboratory fixed indirect costs." Another unique variable is TESTNAME,
which is used to determine the name of the test. On the other hand, Laboratory results
datasets have DSSLARNO, which is the test number in the laboratory results dataset,
and HILO_IND, which is to indicate the abnormality oftest results. These two
variables are only in laboratory results datasets. Both datasets have the SCRSSN
variable for each individual patient to help combine these and other datasets.

37 43 45 46
, , ,

The datasets include both inpatient and outpatient laboratory tests and their
results. All inpatient laboratory tests and the results are placed in each inpatient
encounter record by DSS. The encounter starts from the date of admission until the
discharge date. Outpatient laboratory tests and laboratory results that are done in the
same day are appointed to a single outpatient encounter regardless of how many tests
are performed. Laboratory tests results are presented in a non-numeric field, such as
positive or negative, but DSS software does not read non-numeric values. Therefore,
these non-numeric values need to be translated into a numeric field to be recognized

by DSS software. This step is performed by the DSS Laboratory Results VistA
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extract. These translation values (i.e. 0, 1, 2, 3 .... etc) are placed in the DSS and on the
NDE "laboratory results extracts" (Table III.11 ).
In 2000, DSS started posting the laboratory results. Laboratory test results
started with forty tests in 2000 and new tests have been added in each subsequent year.
There were nine, one, six and three tests added in 2001, 2002, 2003 and 2004
respectively. In 2008, there were seventy one of the most common tests chosen to be
in these datasets (Table III.12).

Access to VA database
To access the VA database, different procedures are required depending on the
type of the dataset(s) needed.

To access VHA Medical SAS Datasets and VHA

Decision Support System (DSS), a Time Share Option (TSO) user account is required.
Also, permission is required to utilize the required datasets. A specific form (VA Form
9957) is required to identify and access the required dataset(s). These datasets are
housed and maintained by the Austin Information Technology Center (AITC).

Advantages and Limitations
Veterans Affairs medical databases are a unique and comprehensive databases
(Table III.13). However, the VA databases have some limitations, such as the validity
of ICD-9 for some diseases. For example, based on a study done in 2009, the ICD-9
for gout disease is not accurate. 47

Another study found that using ICD-9 to identify

viral hepatitis (type B) is not accurate in the VA database.

48

Nevertheless, many

diseases have an accurate ICD-9, such as opportunistic infections and serious bacterial
infections, chronic liver diseases, viral hepatitis (type C), HIV, and many other
83

diseases. 48 ,49 Not all demographic data such as height and weight is available directly
by using medical SAS® databases or DSS databases. The Corporate Data Warehouse
(CDW), another medical database, should be used to access these variables. CDW
requires researchers to submit certain documents if they require access.
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The Health Improvement Network (THIN) database
In the United Kingdom (UK), there are more than fourteen databases
containing clinical and demographical data for patients in the UK.

50

Most of

European countries, such as the UK, Germany, the Netherlands, and Norway, have a
national healthcare system. Having a national healthcare system is beneficial for a
comprehensive and ideal healthcare database. In the UK, the National Health Service
(NHS) is a government agency that is responsible for health services. One of largest
health agencies in European countries, the World Health Organization (WHO) also
considers it to be one of the best agencies. It has over 1.3 million employees,
including doctors, nurses, and technicians. The entire population is required to be
registered with one General Practitioner (GP). Information is transferred if patients
switch to a different GP. To facilitate this information sharing, the UK started to
compile several databases back in the late 1980s. The General Practice Research
Database (GPRD) was formed from the old electronic databases in 1987 by Value
Added Medical Products (VAMP) Health.

50 51
'

The QPRD contains patients'

demographic, medical, prescription, and laboratory data.

52

The Health Improvement

Network (THIN) database was created in November 2002 and includes patients' data
from 1985 until today.

50 52
'

THIN is a result of collaboration between the two large

companies; EPIC and Cegedim. EPIC is a non-profit company that has expertise in
providing primary care patient data and facilitates access to electronic research data. In
addition to providing a data source for research, THIN was created with the aim to
improve the quality and completeness of recording of clinical data in GP practices. It
was created by Dr. Alan Dean, who is also the creator of GPRD. His experience in
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accessing the primary care research data has played a major role in the development of
the THIN database. Cegedim is a European company and parent company ofln
Practice Systems (INPS), which is responsible for developing and providing the vision
practice software. 53 '

54

This software is the same software that is used by GPRD.

is used by over 95% of the primary care practice and health boards in the UK.

55

and

54

Although the THIN database is a new database, it is considered a good alternative
resource for medical research since it has informative, valuable, and has complete data
for each patient. Considering how new this database is, it has a very high possibility
of becoming one of the premier healthcare databases in the UK.
THIN Data

In UK, the general practitioner is considered as gate keeper for the patients as
they are required to visit their GP if they need medical assistance. There are only a
few exceptions to this rule. When the patient visits the GP, the GP will assess the
patient's case and decide to either issue a prescription, refer the patient to a specialist,
refer them for tests, refer to an emergency room, arrange for hospital admission, or
offer advice. A patient does not need to go to the GP first if he/she is receiving
services from an emergency room, a dentist, an optician, or a family planning and
sexual health clinic.

56 57
'

At each practice site, the GP has all the information for the

patient using INPS 's vision software "general practice management software
package." THIN collects a patient's data from participating GP practices without any
disruptions to the GP's work. Then, THIN sends all the data on monthly basis to
EPIC, and EPIC, in turn, sends the datasets to the interested researchers to conduct
therr
. research.

58

All patient data collected by THIN and sent to EPIC are collected
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using de-identified information making a patient's identity no longer available in the
THIN database.

55

C

)

All data collection procedures are approved by the an ethics

committee (Southeast Multi-Centre Research Ethics Committee ; MREC).
Additionally, all studies that are going to be conducted using the THIN database need
to be approved by MREC. In the near future, the approval process will be changed,
whereby the scientific protocol review committee (SPRC ) will replace MREC. Unless
these studies need to collect additional data or need validation, MREC's approval is
still required.

53

In April, 2009, the THIN database had data from over 7 million

patients (approximately 3 million active patients) from over 386 practices. Some of
these practices are also found in GPRD, creating an overlap between GPRD and THIN
in some practices. However, the THIN database contains data from practices that have
never been in GPRD.

55 59
'

THIN database contains demographic, medical, and prescription data at the
patient level. THIN provides a longitudinal record for each patient organized at the
practice level. Furthermore, the data is arranged in four files, or datasets, and two
linked files per practice. The main files contain different patient, medical, therapeutic,
and additional health data (AHD) files, and the two linked files are postcode variable
indicators (PVI) file and dosage records file. These files were created in 2002 and they
contain data for some patients as far back as 1985.

53 58
'

The patient file contains

complete demographic data, including the patient unique identifier, age, year of birth,
gender, death date, registration date with the practice, and date of leaving if the patient
leaves a specific practice. The medical file contains all health and disease conditions
and symptoms recorded at the GP office as well as the patient unique identifier. These
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files include the event date, diagnosis, diagnostic data (e.g. X-ray, CT scan, MRI and
others), episode type, location of consultation, medical history, and referral data
(Table III.14).

53 58 59
' '

If the patient is transferred to secondary care, all the data from

their secondary care is sent back to the GP and entered into the system.

58

This data

consists of very detailed information including type of specialty; hospital admission;
hospital discharge, diagnosis, and medication; outpatient consultation diagnosis;
. .
investigation;
an d t reat ment out come.

52 58
'

All health conditions and diseases in THIN databases are coded using the
READ clinical classification version 2.

60

READ codes are alphanumeric codes that

define diseases using a hierarchical nosologic system (Table III.15).

61 65
-

The code

terms used in READ are related to the observations (signs and symptoms), diagnoses,
procedures, and laboratory and radiologic tests.

53

The therapy file includes

information about prescription data. After the GP enters the prescription data, one
copy is sent to the pharmacy and one printed copy is given to the patient to take it to
the pharmacy.

58

Using this procedure creates a medication record for each patient that

includes all medication prescribed. for the patient since his or her first day of
registration at the GP office. Medication information in the THIN database includes
patient unique identifier, product code, British National Code (BNF), date of
prescription, formulation of the drug, dose strength of the drug, indication for
treatment, duration of prescription in days, route of administration, prescriber
identifier, and prescription type (acute or refill).

52 59
'

Drugs are coded using First

Databank' s Multilex® coding system and the BNF coding system (Table 111.16).
58,66,67

There are three codes for BNF (BNF code 1, BNF code2, BNF code3) each
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representing different groups of medications. Therefore, some medications that may
have more than one BNF code. For example, aspirin can be classified as a nonsteroidal anti-inflammatory drug (NSAID) and an anti-platelet.

68

The above

procedure ensures most medications are well recorded in the THIN database with only
a few exceptions. Controlled substances, immunizations, and drugs administered
during home visits are not issued from the computer but are entered into the system at
a later time. Therefore, there is a chance of under-recording these groups of
medications. Over the counter (OTC) medications may also be included in the THIN
database if the OTC drug has been prescribed by the GP.

58 68 69
, ,

Medication that is prescribed outside the GP office by hospital physicians and
specialist physicians usually is not recorded in the system, excluding it from the THIN
database. However, if the patient continues to take the medication that he/she started
taking in the hospital, the drug will be recorded in the database because the patient
will follow up with the GP.

58

Some of the medications data from outpatient specialty

care may also be found in the GP summary.

58

The additional health data (AHD) file contains supplemental information such
as patient unique identifier, GP consultations, details from other healthcare
interventions, patient's height and weight, allergies, vaccinations and immunization,
contraceptive prescriptions, pregnancy, birth details, death details, laboratory tests
and results, and life style information including smoking and alcoho 1 intake.

53 59
'

Recently, the pathology laboratory has been electronically linked to many practices
making it easier to record patient tests results and store them in their records.
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Some of the data in AHD can be found in other files. For example, data on
smoking and alcoho 1use can be found in medical records, and contraception data can
be found in therapy files and in medical files.

68

In addition to these main files, EPIC creates Postcode Variable Indicators
(PVI). PVI files provide unidentified postcodes which link the area based on
socioeconomic, ethnicity, and environmental characteristics to help researchers who
are planning to conduct a study using THIN to understand the differences between the
areas to avoid any potential bias or confounders that could affect the study. Under the
PVI file, there are information related to the degree of deprivation, ethnicity, and the
degree of pollution (with particulate matter 10 (PMI 0), sulfur dioxide (S02) and
nitrogen dioxide (N02). Each one of these three variables is matched to the UK
postcode. The ethnicity is categorized into white, black, mixed, Asian, and
other. 53,58,59

Additional information about any patient may be obtained through the
Additional Information Service (AIS), which includes· information such as death
certificate, unidentified questionnaires filled out by the patient or by the GP, and a
specific intervention (e.g. specific diagnostic test to confirm a specific diagnosis).

59

Validation of THIN database
Although the THIN database, created in 2002, is considered a new database,
many studies have been conducted using this database. 70 -73 Validity of the information
in the database needs to be investigated, especially the diagnosis of the diseases. A
study in 2006 investigated the validity of THIN database through conducting different
90

case control studies to study the association between disease and drug use (e.g. peptic
ulcer medication and Non-Steroidal Anti-inflammatory Drugs (NSAIDs) use) and
between diseases (hypertension and stroke). The results of the four studies were
consistent with the information in the literature. Additionally, in their results, they
found that the results were identical between the GPRD practices and non-GPRD
practice. In their conclusion, they stated that the results of the different studies support
the validity of data within the THIN database.

55

Another study, assessed the quality

of the THIN database by assessing the quality of the practices that participated in
THIN. Two hundred thirty six practice sites agreed to participate. They concluded
that all of these practices demonstrated a high level of completeness ofrecording the
clinical information in many of the practices.

74

Recently, many studies have been

done to validate the THIN database and it found that the data in THIN database are
valid and accurate . 55 ' 75 In addition to these studies, researchers can request EPIC to
validate the information of their study using the THIN database.

68

THIN database files structure
THIN provides the entirety of each file in the American Standard Code for
Information Interchange (ASCII) format, a standardized fixed width text format,
making it "user friendly" for researchers. THIN database users can load and import the
files into different database and statistical software such as Oracle®, Statistical
Package for the Social Sciences (SPSS®), Structured Query Language (SQL),
Statistical Analysis Software (SAS®), and Microsoft Access®53 . All of these files have
a patient unique identifier (patid) allowing all of the files to be linked together using
patid. In addition, all files are sorted by patid and by date.
91

Access
EPIC is responsible for providing access to the THIN database. 53 ' 59 They
facilitate access to the data in several ways. First, they provide raw datasets to the
researching organization to perform their own research. They also perform some
statistical analysis based on the submitted protocol. Furthermore, they help obtain
additional information from the GP and coordinate with AIS Company. EPIC
provides the dataset on hard-drives, tapes, and compact discs (CDs). 53 ,7 6 Researchers
from the UK as well as other countries worldwide can access THIN database to
conduct their research. Any researcher wanting to use the THIN database to conduct a
study needs to get an ethical approval for their protocol from the UK MERC.

Advantages and limitations of THIN database
The THIN database has many advantages for both the health system in the UK
and for research studies (Table III.17). It helps to improve the quality of clinical data
recording and, subsequently, will improve the quality of healthcare in the UK. THIN
offers many training sessions for the users (GP and researchers) to become familiar
with the database.
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THIN is a computerized database, allowing for the compilation of

complete and updated data for each patient. Therefore, any investigator can obtain
new and additional patient information for a study. It is a population-based database,
so selection bias will be minimized making epidemiological study more valid.

58

In

addition, recall and interviewer biases are not a problem since all information that has
been collected is not based on patient recall. Additionally, in conducting
epidemiological study, the cases and controls are derived from the same type of
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population. Therefore, all the criteria inside the database were applied to all patients
(including cases and controls). Another advantage of the THIN database is that it
contains longitudinal data allowing studies with long follow up to be conducted easily.
Another advantage of THIN database is the size of database. It has a large
number of patients enabling many health conditions, including rare conditions, to be
studied. The THIN database has been validated through many studies, and these
studies have found the information inside THIN database to be valid and complete.
55 ,75

This is one of the important issues for any database. However, additional studies

are still needed to validate different disease states.
Finally, researchers have the ability to access the original medical records
pertaining to the topic being studied. The researcher can request a copy of a patient's
medical record (non-electronic). There will not be any identification for the patient on
the medical record, but this service can help the researcher in many aspects such as
validating the information and getting detailed information about the patient.

68

However, there are some disadvantages to using the THIN database. As a UK
population database, THIN database has several limitations: first, it can only be
generalized to UK population, not other populations. Secondly, the data in the THIN
database may not be complete enough given the fact that there are a lot of
communications between the GPs and specialists and hospitals that may not be found
in the database. Some conditions and symptoms may not be found in the THIN
database such as headache and cold symptoms, especially if the GP did not prescribe
any medication for the patient. In addition, information about OTC medications are
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not available in the databases except if they were prescribed by the GP. Also,
medications that were prescribed by specialists may not be found in the database.
Psychiatry medications may also not be found if the patients were treated by
community mental health teams. As with many databases, obtaining complete race and
ethnicity information is still a problem with the THIN database. ethnicity information
is available but incomplete.

78

Finally, the THIN database is very costly, and the

researcher must pay extra for additional services (i.e. accessing non electronic medical
records).
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The Norwegian Medical Database
Norway, a Scandinavian country in Europe, has a population of 4.8 million as
of 2009.

79

The population has increased by 1. 5 million since 19 5 0.

80

This increase in

the growth rate was caused by a rising birth rate, prolonged life expectancy, and an
increased number of immigrants to Norway. Norway is considered to be among the
highest ranked nation in the number of immigrants. Norway has many strengths in its
educational and economic systems.

81

More than 57% of the population aged 16 and

more had completed their secondary school, placing Norway among the most educated

. wor Id w1.d e.
countnes

81 82

'

The healthcare system in Norway is structured on three levels: the national
level, the regional level, and the local level. The national level is responsible for
establishing and providing necessary legislation, determining the national health
policy, and funding the health services.

81 83
'

The regional and local levels are

responsible for providing the health care services through a network of hospitals,
primary care clinics, psychiatric clinics, pharmacies, outpatient clinics, dental clinics,
ambulance services, and other health services.

81

Overall, the regional authority is

responsible for specialist healthcare while the local level is responsible for primary
health care. The Ministry of Health and Care Services is responsible at the national
level. Norway has an excellent environment to have a good healthcare system. Its
national health system grants each citizen the right to health services access regardless
of their geographic location or economic and social status.

81

This allows each patient

to go to the primary care or hospital when he/she is sick. Access to healthcare creates
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data about most people's health status that can be used to build a comprehensive
database for most of the population in Norway.
The Royal Norwegian Ministry of Health and Care Services (Helse-og
omsorgs departementet ) is the superior agency that is responsible for providing the
healthcare services to the Norway population. There are several agencies that are
under the ministry of health umbrella that have an important role in the healthcare
system and medical database development in Norway, such as the Norwegian Institute
of Public Health, Norwegian Board of Health Supervision, Norwegian Medicines
Agency and Norwegian Directorate of Health.

81 84
,

Patient pathway

Patients who seek medical advice or therapy must visit the general practitioner
(GP) first . Approximately, 99% of the population is registered with one general
practitioner. The ministry of health gives the freedom to the patient to choose a GP
among from a list in their local area.

81 85
'

The GP is usually located at the

municipality' s level and acts as a gatekeeper to further medical care. The GP will take
one of the following actions: diagnose the patient and give the suitable treatment or
make a referral if the patient needs to be seen by a specialist physician. The specialist
physicians are located at the specialized healthcare centers or institutes. The
specialized healthcare centers include hospitals and specialized medical services such
as laboratory services, radiology services, and special care for alcoholics and or
persons with drug addiction. Furthermore, it includes somatic and psychiatry
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institutes.

81 84 86
' '

Each regional healthcare authority is responsible for running these

centers to deliver high quality specialized healthcare to each patient in the region.

81

Registries and databases
As mentioned previously, Norway has a good healthcare system to build good
registries and databases. In Norway, there are different types of databases that focus
on different areas at different levels (i.e. hospital level and population level). The two
types of electronic databases at the hospital level are the local electronic level and the
national electronic level. At the local electronic level, there is an electronic database in
the hospital that includes all patients' information during the hospitalization. This
information includes the patient identification number, admission and discharge dates,
codes for one primary diagnosis and secondary diagnoses, and codes for surgical
procedures performed at the hospital.
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The national electronic database, "The

Norwegian Patient Register," includes patients' information from all hospitals in
Norway. The Norwegian Patient Register includes an anonymous patient number,
which contains the number for each year and number for the hospital. It also includes
one primary diagnosis and two se~ondary diagnoses.

87 88
'

More than 90% of the

primary care physicians and hospitals already use the electronic health record system
(EHR). This method of electronic documentation has many benefits including building
the electronic database and reducing the risk of losing important clinical documents.

89

Other types of specific databases or registries are The Cause of Death Register,
The Cancer Registry of Norway, The Medical Birth Registry of Norway, The
Norwegian Surveillance System for Communicable Diseases (MSIS), The

97

Tuberculosis Registry, The Childhood Vaccination Register (SYSV AK) and The
Norwegian Prescription Database.

9

°Furthermore, there are more specialized registries

like the National Injury Register (NIR) and Database over Occupational Injuries and
Occupational Diseases (Table III.18).

91

These databases and registries are run by

different institutes such as The Norwegian Institute of Public Health, Institute of
Epidemiological Cancer Research Statistics of Norway, and The Association of
Norwegian Insurance Companies.

90 91
'

Additionally, there are other discontinued

databases that have available data and can still be accessed.
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Previous databases were used to establish a new monitoring system that
combined many health indicators that make it a comprehensive database
(Table III.19).
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Since the official registries and databases in Norway have the patient

unique personal identification number, it became a very useful tool to link these
registries together to make this monitoring health system. Additionally, this method
assists linking the health information with other information such as education and
socioeconomic data. It is called Norhealth, or the Norwegian Health Information
System, and it is used to monitor health related conditions over time. Having a system
like Norhealth helps to produce a very good health monitoring system and high quality
research using the variety health indicators from different types of registries.
Norhealth includes basic elements such as population and socioeconomic factors, risk
and protective factors, morbidities and diseases, births and abortions, health services
and treatment, mortality, determinants of health (lifestyle, biological measurement,
vaccination), and social inequalities in health. As of 2008, there are fifty health
indicators with over seventy health indicators slated in the future.

98

92

The Norwegian Prescription Database (NorPD) "Reseptregisteret"
In Norway, their drug database has different transition levels. In 2000, the
Royal Ministry of Health and Care Services decide to established a national
prescription registry. The Department of Pharmacoepidemiology was established in
2002 under Division of Epidemiology at NIPH.

93

The Department of

Pharmacoepidemiology is responsible for drug consumption in Norway, developing
and maintaining the anatomical therapeutic chemical (ATC) classification system,
defining daily doses (DDDs) for international use and to run NorPD. Additionally, the
World Health Organization (WHO) Collaborating Centre is located at the Department

. 1ogy.
of Pharmacoep1.dem10
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In October 2003, the final regulation on the Norwegian prescription database
was released to achieve many objectives. The regulation obligates pharmacies in
Norway to submit all prescription data "electronically" to NIPH on a monthly basis.

95

The main objective ofNorPD is to collect and process the data on drug utilization for
both humans and animals. In addition to this main objective, NorPD has several aims
(Table III.20).

93 96
,

In January 2004, all pharmacies in Norway started to send data on

dispensed prescriptions to NIPH. Each year, the Pharmacoepidemiology Department
at NIPH receives data for over 34 million prescriptions from over 600 pharmacies in
Norway. Since all pharmacies have a computerized system for entering and dispensing
the prescribed medications, this helps in transmitting the data to NIPH. From
NorPD's establishment until 2007, over 150 million records are available for over 4.2
million patients.

93 97
,
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In NorPD, there are several variables for every record for each element in the
prescription pathway (i.e. patient data; prescriber data, drug data and pharmacy data).
Some examples of these variables are the patient identification number, patient age
and gender, prescriber specialty, prescriber profession, number of drug packages
dispensed, ATC codes and DDDs, date of dispensing, and pharmacy name and license
number (Table III.21). NorPD has this data for all dispensed prescriptions and over
the counter (OTC) medications prescribed by a physician.

Nonvegian databases and pharmacoepidemiological research
In addition to being important in conducting a pharmacoepidemiological
research, NorPD is used to produce statistics on medications in Norway such as
number of medication users; stratification of users by variables such as age, sex,
county, and other variables; turn over in dosage; and any statistics about the variables
in NorPD.
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NorPD can be used alone and with other databases as well. It can be used alone
to conduct research related to medications because all variables regarding medications
are available in NorPD. Also, it can be used alone to conduct
pharmacoepidemiological research given that some medications can be used as proxy
for diseases in cases where there is no data about diagnosis. The main advantage in
Norway is that most of the databases contain the patient's personal identification
number allowing these databases to be linked together using the patient identification
number.

93 98

.

' NorPD can be lmked to several other databases. For example, a

researcher could study the protective effect of some medications on different type of
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cancers by linking NorPD with the Cancer Registry or the negative effect of
medications used during pregnancy can be studied by linking the Medical Birth
Registry with NorPD. This feature makes the structure of the health system in Norway
unique and the epidemiological research very applicable and beneficial. Since the
establishment ofNorPD, many pharmacoepidemiological studies and reviews have
been conducted. Since the first publication in 2004, the number of publications has
increased through the years reaching up to twenty five publications in 2007.
period of 2004-2009, a total of around 50 publications had utilized NorPD.

99
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In the
This

number is expected to increase due to the increased popularity of the database and the
facilities presented by Norwegian Institute of Public Health.
Accessing NorPD
The Norwegian Institute of Public Health facilitates the access ofNorPD for
researchers who are interested in conducting pharmacoepidemio logical research. The
researchers can access the data without paying any charges for the data itself The
researcher will only pay ifthere is any administrative work or file processing that must
be done in order to obtain the data. In case where statistics related to the medication
pattern used in Norway, NorPD has a website that includes all information related to
the database, and from that website, one can create a report related to any variable
related to medications (http://www.norpd.no/Prevalens.aspx).
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,ioo

NIPH requires detailed information about the researcher, co-researchers, the
institute, and the protocol of the study to make sure that the aim of the study is
compatible with the NorPD's aims.
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Advantages and limitations
The health system in Norway has many factors that make it one of the most
unique health systems worldwide. These factors help to establish and maintain
distinctive databases and registries. It is well known that having a national "social"
health system is considered an important factor to have an ideal health database.

23
'

Norway has several advantages pertaining to the databases. It has several databases
that specialized in areas such as cancer, medical birth, death, and communicable and
non-communicable disease. Having a specialized database in each area, it is important
to have a patient's complete and comprehensive data within these specialized
databases. For instance, the data in the cancer registry is almost 100% complete.
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In

addition to having specialized databases, Norway has more than eight databases that
cover most health areas in addition to medication data. Since most individuals are
registered within one primary care clinic, most patients have their health information
in these databases. Therefore, any study done using these databases will be considered
externally valid (i.e. can be generalized to the Norwegian population) All these
databases have the eleven-digit p€rsonal identification numbers (person nummer) that
makes it easy to link all these databases together simply by using this number.
Therefore, it is possible to conduct different epidemiological researches in different
areas. In addition, performing a system of monitoring allows researchers to follow the
trend of the diseases in Norway, and post-marketing surveillances to detect the signals
for adverse drug reactions as well. Furthermore, it is a relatively inexpensive database
for researchers to access.
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Like other countries' databases, Norwegian databases have some limitations.
The validity of the diagnoses in these databases is not clear. One study found that the
number of certain diagnoses in these databases are overestimated or underestimated,
possibly caused by the transition steps that take place until the data reaches the final
destination. Also, the results of any study used in the Norwegian database are
generalized to Norwegian population only. Some of these databases have missing
information; in case ofNorPD, it does not include OTC medications data (except
prescribed OTC), the indication for use is not mentioned, and the medications
dispensed to the patients in the hospitals and nursing homes are not available in
NorPD.
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Conclusion
In conclusion, each database has its own strengths and limitations.NIS can
answer many research questions related to healthcare utilization and healthcare cost,
but it is not the best database to answer questions related to medication exposure since
there is no detailed information about medications. The latter research question can be
investigated thoroughly and accurately by using the VA databases because these
databases contain enough data on patient medications. Many other research questions
can also be answered using VA databases because they have ample data on most
clinical aspects as well as economic aspects. Pharmacoepidemiologic,
pharmacoeconomic, and other behavioral studies can be performed using the VA
databases. However, any study conducted using VA database will only be generalized
to the VA population. This problem is not a big issue in countries with a social
healthcare system such as the UK and Norway. The conclusions of studies that use
the THIN database in the UK can be applied to the entire UK population. This is also
true of studies that used the Norwegian database.

Th~

THIN database shares similar

characteristics of the VA database in its ability to answer many research questions
related to diseases and medications. Finally, the Norwegian databases are very
interesting and well-organized databases. The major strength of these databases is that
they can be linked together to produce large amounts of patient information to conduct
many studies. Researchers from inside as well as outside Norway should start to
utilize these databases. The major difference between U.S databases and European
databases is a result of the type of healthcare system in each country. As mentioned
before, the social healthcare system is an ideal environment to produce a good
104

database. This can be found with the THIN database and the Norwegian databases.
The VA database also has similar attribute because VA health care system somewhat
resembles a government-run, universal healthcare system.
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Table 111.1: Essential elements available in nationwide inpatient sample

Primary and secondary diagnoses
Primary and secondary procedures
Admission and discharge status
Patients demographic data
Payment resources
Total charge
Length of stay
Hospital characteristics
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Table 111.2: Areas and topics that can be answered through using nationwide
inpatient sample database
Analyses of states and communities
Health care cost inflation
Hospital financial distress
Use and cost of hospital services
Utilization of health services by special populations
Medical practice variation
Medical treatment effectiveness
Quality of care
Impact of health policy change
Access to care
Diffusion of medical technology
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Table 111.3: Examples of research questions that can be answered by nationwide
inpatient sample
Research question examples

Type

What is the cost of treating asthma?

Economic

What is the epidemiology of meningitis?

Epidemiology

What is the mortality rate in patients treated with

Outcome

thrombolysis?
Are there racial differences in seeking health care?

Access to care

What is the difference between patients going to teaching

Medical practice

hospital and patients going to other hospitals?
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Table 111.4: Primary users of nationwide inpatient sample data
State and federal government agencies

Pharmaceutical companies

Hospital information system firms

School of pharmacies, public health
and business

Healthcare systems

Health services researchers and policy
analysts

Health insurance companies

Health professions societies

Hospitals

Managed Care Organizations (MCOs)
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Table 111.5: Advantages and limitations of the nationwide inpatient sample
database
Advantages

Limitations

Sponsored by AHRQ

Does not include reliable pharmacy
data

Largest inpatient database

Does not include data outside the
hospital system

Inexpensive

Race and ethnicity data is incomplete

Ability to perform analysis of trends over

Does not include all hospitals

time
Generalizability
Ability to study rare diseases
Includes different types of insurance
sources
Can be used with different type of
statistical packages (SAS®, SPSS® and
Stata®)
Contains health information as well as
economic information
Easy to use
Contains detailed information about the
datasets
Web-based training
._
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Table 111.6: Data sources within Veterans Affairs database
,...-

Data source
r-The National Survey of Veterans

VHA Assistant Deputy Under Secretary
for Health (ADUSH) Enrollment
Monthly File
Beneficiary Identification & Records
Locator System (BIRLS)

Description
Socioeconomic background.
Military background.
Health status and healthcare use.
Veterans' understanding of and use of
VA benefits.
National statistics on VHA
expenditures, enrollment, and patients.
Death File.
Veterans who have applied for VA
benefits.
Veterans discharged from the military
service since March 1973.
Recipients of the Medal of Honor
Service members with accounts for VA
education benefits.

VA Decision Support System (DSS)

Clinical and financial data for inpatient
and outpatient care.
DDS production database that combine
cost data, clinical data and other data.
DSS National Data Extracts that include
several extracts such as Pharmacy,
Laboratory and other types of extracts.

The VA-Medicare Data Merge Initiative

This initiative sponsored by VA to assist
the researchers to access Medicare
database.
Several Medicare data can be accessed
such as Medicare Data File
Documentation, Medicare Current
Beneficiary Survey (MCBS) and United
States Renal Data Systems (USRDS).
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.-The VHA Medical SAS Datasets

The National Prosthetics Patient
Database (NPPD)

The Pharmacy Benefits Management
(PBM)

Resident Assessment Instrument Minimum Data Set (RAI-MDS)

It's extracted from the National Patient
Care Database (NPCD).
It is the most utilized medical dataset.
They include all inpatient and outpatient
care data.
It developed by the Prosthetic and
Sensory Aids Service Strategic Health
Care Group (PSAS).
It includes information about orthotic,
prosthetic and sensory devices
dispensed to veterans nationwide.
NPPD available since 2000.
National database that include all
prescription medications that dispensed
with VHA system.
It comprises all inpatient intravenous
and unit dose prescriptions in VA
facility and outpatient prescriptions.
It includes data about dosing
instructions, National Drug Code
(NDC), product name, ordering
provider, quantity dispensed ,drug
product costs, formulary status, and VA
drug class
In includes controlled prescription
information.
RAl-MDS defined by VHA as "a core
set of screening, clinical and functional
status elements, including common
definitions and coding categories, that
forms the foundation of the
comprehensive assessment for all
residents of long-term care facilities".
Data available since 2001.
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The VA Vital Status files

The file comprises the death dates from
all VA resources.
It comprises from two files, the master
and mini files.
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Table 111.7: The four major datasets in the Medical SAS Inpatient Datasets and
their definition
.-Dataset

Contained Data

Main section

Data for the patients' inpatient stay.
Demographics, primary/secondary
diagnoses and other variables (up to 91
variables in 2006).

Bed section

Include the patients' data that ·are
under a specified physician treating
specialty during the inpatient stay.
It includes Primary/secondary
diagnoses and length-of-stay and other
variables up to 48 variables in 2006.

Procedure section

One day procedure (up to four
procedures) during the inpatient stay; it
has up to 25 variables in 2006.

Surgery section

One day surgery (up to 5 surgeries)
performed in the main or specialized
room during the inpatient stay; it has
28 variables in 2006.
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Table 111.8. Description of the National Data Extracts datasets
Narrative

Acronym

Availabilty

Discharge

Discharge datasets includes one record for
every hospital stay in a specific fiscal year.
They were implemented in 1999 and it has
several variables such as number of X-rays,
discharge DRG, different type of costs and
other variables.

DISCH

FY19992009

Outpatient

Outpatient datasets include services that are
not available in the NPCD.
They have more detailed cost data and some
clinical data.
The files are divided to different group
because of the big size.

OutPat

FY19992009

Treating
Specialty

Treating specialty datasets could have more TRT
than one record for each hospital stay.
They are divided into different sections
based on the month and treating specialty of
the provider for each stay.
It is associated with the location such as
medical care, surgical ward or long-term
care unit.
LAR
Laboratory results dataset includes
laboratory results for defined number of
laboratory tests.
It has both inpatient and outpatients
encounters.

.-NDE
dataset

Laboratory
results
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FY19992009

FY20002009

Laboratory datasets include record for every
individual "patient" laboratory tests for both
inpatient and outpatient encounter during
the extract period.

LAB

FY20022009

Radiology

Radiology datasets include data such as
type, cost and number ofradiological
procedures that performed in the Diagnostic
Radiology and Nuclear Medicine
Departments for every encounter.

RAD

FY20022009

Pharmacy

Pharmacy datasets provide data on drugs
that used in both inpatient and outpatient.
They include prescription, unit dose, and IV
pharmacy detail.

PHA

FY20022009

Labo rat
ory
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Table 111.9: Examples of variables in the Pharmacy National Data Extract
Variable

Definition

COMP

Patient has received the medication by mail.

DAY_SUPPLY

Number of the days' supply for each drug (maximum 180
days to avoid errors)

DRUGDESC

Drug description

ACT_COST

Actual total cost
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Table 111.10: Sources of the laboratory and laboratory results National Data
Extracts
Source

Data

VistA Data File (#63)

Lab workload

Laboratory

and the Referral Patient

Laboratory
result

~

~

~

~

~

~

~

~

File (#67)
Patient File (#2) and the

Patient's demographic

Referral Patient File

data

(#67)
VistA Patient

Inpatient information

Movement file (#405)
V istA Patient Care

Encounter information

Encounter file

(e.g. date)

DSS

Cost, product and
department information.
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Table 111.11: Examples of numeric value for non-numeric laboratory test results
.-

Non-numeric value

Numeric value

Negative, Non reactive

0

Positive , Reactive

1

Borderline results

2

Test has been done

5
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Table 111.12: Examples of Laboratory Tests those are available in Laboratory
datasets
r-

Availability year

Result ID number

Potassium (MEq/L)

FY2000

2

Sodium (MEq/L)

FY2000

3

Blood Urea Nitrogen "BUN" (Mg/dl)

FY2000

5

Creatinine Clearance (Ml/min)

FY2000

11

Digoxin (Ng/ml)

FY2000

7

AST "Aspartate Transaminase" (U/L)

FY2000

9

ALT "Transferase Alanine Amino" (U/L)

FY2001

45

Hematocrit (%)

FY2002

50

INR "International Normalized Ratio"

FY2003

52

Creatinine GFR (ML/MIN/1. 73M2)

FY2006

66

Laboratory test (Unit)
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Table 111.13: Advantages and limitations of the VA databases
Advantages

Limitation

Largest database in the US

Majority are male

National database

Contains variables reported by patients
such as using illicit drug

Includes most of the information that

Smoking status is not well documented

required to conduct a research (i.e.
diseases, medications, laboratory,
radiology, all patient demographics .. etc)
Most of the databases are free to access
Uses single unique identifier to lin dataset
in fiscal year
Most diseases' definition by ICD-9 have
been validated
Many measures are taken to guarantee the
patient privacy
Help and technical support is very active
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Table 111.14: Some variables in the THIN database and their original sources
Variable

Original source*

Patient identifier (Patid)

All files

Age

Patient file

Sex
Death date
Event date

Medical file

Read medical code
Hospital referral
Medical history
Prescription date

Therapy file

Drug code (multilex code)
BNF codes
Dosage and duration of prescription
Height

Additional Health Data (AHD) file

Weight
Vaccination
Smoking and alcohol intake
Pregnancy and birth details
Laboratory tests and their results
*Some variables can be found in more than one source.
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Table 111.15: Examples of READ codes in the THIN database
Read code

Description

D21z

Anemia

G33

Angina pectoris

M03z000

Cellulitis Not otherwise specified (NOS)

FOO ..

Bacterial meningitis

713 ..

Breast operations

535 ..

Standard chest X-ray
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Table 111.16: Examples of British National Formulary (BNF) drug codes in the
THIN database
BNF code

Drug name

Therapeutic group

05.01.0 l.03a

Amoxicillin

Broad spectrum
penicillins

06.02.0 l .OOa

Levothyroxine

Thyroid hormones

02.04.00.00b

Bisoprolol

Beta-Blocker

02.06.01.00a

Glyceryl Trinitrate

Nitrates

07.03.02.0lc

Levonorgestrel

Oral progestogen-only
contraceptives
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Table 111.17: Advantages and limitations of the THIN database
Advantages

Limitations

Computerized

Generalized to UK population only

Population-based

Not fully completed

Longitudinal

Costly

Large number of patients
Validated
Access the original medical record
Confidentiality

125

Table 111.18: Examples of databases available in Norway
Description
- Includes the cause of death data since
1922.
- It used to publish statics about the
causes of death annually.
- It has different information in addition
to the underlying cause of death like
age, gender, region of the person and if
it is suicide or not.
- It has information about death due to
alcohol narcotics and medications.
- It runs by statistics Norway with a
cooperation with the Norwegian Institute

Database
The Cause of Death Register

90

of Public Health
The Cancer Registry of Norway

90 91
•

The Medical Birth Registry of Norway

90 102
•

- The purpose of this registry is to prevent
the caner by knowing the reasons that
cause cancer and most common cancers,
to have a real statistics about the number
of cancer cases and the distribution of
these cases among Norwegian
population and to have a good resource
to conduct epidemiological researches
re lated to cancer.
- It has all cancer cases since 1953 to date
and it has over 500,000 cancer cases.
- It has a statistics about the major
common cancer types among men and
women.
- The reporting system to this registry is
consider of very complete (near to
100%)
- Patients can be linked using their unique
personal identification number
- The aim of this registry is for
conducting surveillances about the
newborn babies' health and the
pregnancy outcomes and to conduct
epidemiological researches related to the
babies' health and to pregnancy
outcomes.
- It is a national registry in Norway and
includes all babies born there.
- It has all babies' data since 1967
therefore, it considered the world's first
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medical birth registry
- Can be linked with other registries in
Norway so it a great resource for
research in combined with other
registries
- The registry is responsible by the
Norwegian Institute of Public Health and
the University of Bergen

- MSIS has data about all infectious
diseases at national and local level.
- It is the official monitoring system for
communicable diseases in Norway.
- The sources of MSIS are from
physicians, hospitals and laboratories.
- The information include; disease name,
month and year of diagnosis, age group
of the patient, county ofresidence and
place of the infection and the mode of
transmission in case of HIV, syphilis,
gonorrhea and viral hepatitis.
- MSIS is responsible by the Norwegian

The Norwegian Surveillance System for
90 103 104
Communicable Diseases (MSIS) ' '

Institute of Public Health
The Tuberculosis (T.B) Registry 9 o,10s, 106

- It is responsible by the Norwegian

-

-

-

The Childhood Vaccination Register (SVSVAK)
90

Institute of Public Health under department
of infectious disease epidemiology.
It has all TB cases since 1962
All counties in Norway are required to have
TB control program.
All the cases data should be send to the
Tuberculosis Registry
The aim of the registry is to detect early TB
cases and treat it and to conduct
epidemiological research related to TB
disease.
The sources of the registry are physicians,
antituberculosis prescriptions and
laboratory.
It has important variables such as; patient
age, gender, site of the disease and birth
place.

- The aim of the registry is to make sure
that all children are vaccinated and to
conduct researches related to vaccines.
- All centers are required to register the
child ' s immunizations to the registry.
- It also used to monitor the adverse effect
of the immunizations.
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- It is under the department of vaccine
and immunity at t the Norwegian Institute
of Public Health
- It has information about the child such as
child name, unique identification personal

The National Injury Register (NIR)

90 91
'

number, family address, vaccine name
and vaccination date and any adverse
events.
- It is responsible by the Norwegian
Institute of Public Health

Database over Occupational Injuries and
Occupational Diseases 91

- It was established in 1985 and it has all
injury cases till now.
- NIR are using other register as
references such as The National
Register of Deaths, The National
Hospital Discharge Register and The
National Injury Sample Register.
- The variables in NIR include age, sex,
place of residence, type of accident,
mechanism of injury, type and severity
of injury, product involved, time and
event of injury and the medical
information on the site.
- The aim of NIR is to have information
about the number and type of injuries
for statistics and prevention purposes
and to conduct epidemiological
research.
- It was established in 1990.
- It is responsible by the Association of
Norwegian Insurance Companies.
- It includes all Occupational Injuries and
Occupational Diseases that reported to
the insurance companies.
- The variables are unique identification
personal number, degree of disability,
types of contact, the part of body
injured, item caused the injury, the
diagnoses "for occupational diseases"
and the worker's compensation.
- The aim of the registry is to use the
information in the database for
prevention purposes and for research
purposes.
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Table 111.19: Resources for Norwegian Health Information System ("Norhealth")
Source name
Cause of Death Register
Medical Birth Registry ofNorway
Tuberculosis Registry
Norwegian Patient Register
Statistics Norway' s Health Interview Survey
Cancer Registry of Norway
Norwegian Prescription Database
Norwegian Surveillance System for Communicable Diseases
Childhood Vaccination Register
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Table 111.20: Aims of the Norwegian Prescription Database (NorPD)
To explain the pattern of medication utilization and monitor the trends of utilization
over time
To function as a base resource for drug related statistics to be used by authorities to
assess the quality of drug prescription, controlling and planning
To function as an internal control for prescribers to improve the quality of prescribing
practice.
To function as the main resource for medication and pharmacoepidemiological
research.
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Table 111.21: Variables available at Norwegian Prescription Database (NorPD)
Element

Variables

Patient

- Encrypted personal identification
number
- Gender
- Date of birth
- Place of residence
- Date of death
- Encrypted personal identification
number
- Gender
- Date of birth
- Profession
- Specialty
- Drug brand name, strength ,package
size and number of package
- ATC code and DDD
- Category of prescription
- Code of reimbursement
- Date of Dispensing
- Drug cost
- Area of a_QQ_lication and prescribed dose
- Pharmacy name
- License number
- Place of pharmacy (municipality and
counb')

Prescriber

Drug

Pharmacy
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